1

1

CURRICULUM VITAE

Taner Demirer, M.D, FACP Professor of Medicine and Hematology/Oncology

PERSONAL INFORMATION Date of Birth : 03/27/61 Place of Birth: Ankara, Turkey. Home Address: Üniversiteler Mahallesi, 1623. Sok No: 7 Bilkent-Ankara

TURKEY

Professional address: Ankara University Medical School, Dept. of

Hematology/Oncology and Bone Marrow Transplant Unit,

Cebeci Hospital, Ankara-Turkey.

Cell Phone: +90-532-325-1065 Business Phone: +90-312-595-7376 Fax: +90-312-466 -3717 E-Mail: demirer@medicine.ankara.edu.tr

SPECIALITIES: American Board Certified in Internal Medicine (1993) American Board Certified in Medical Oncology (1997) American Board Eligible in Hematology

2

2

PRESENT and PAST ACADEMIC RANK AND POSITION

Research Associate, Dept. of Hematol / Oncology, Chicago Medical School (USA) 1988-

1989

Fellow of American College of Physicians (FACP) (July 1996)

Clinical Investigator, The Fred Hutchinson Cancer Research Center, Seattle (USA), 1996-

1997

Professor of Medicine, Ankara University Medical School, Dept. of Hematology and Bone

Marrow Transplant Unit (CIC 617). (1997- )

Chairperson of the EBMT Solid Tumor Working Party (March 2001-2007).

Member for FECS (Federation of European Cancer Societies) (March 2001-2007).

President of the Turkish Cancer Advisory Board (June, 2003-2005).

Member of Blood and Blood Products Committee of Turkish Ministry of Health (1999-

2004).

Member of the Imported Blood Products Committee of Turkish Ministry of Health 1999-

2002).

Member of the Apheresis Committee of Turkish Ministry of Health (2000-2003)

Chief of Drug Registration and Licensing Committee of Turkish Ministry of Health (2001-

2004)

National Director of the EU 6th Framework Program (2002-2003)

3

3

Principal Member of The Turkish Academy of Sciences (2012- )

Member, Stem Cells Working Group of The Turkish Academy of Sciences (2012- )

Principal Member of The European Academy of Sciences and Art (EASA) (2013- )

Director, Cancer Working Group of The Turkish Academy of Sciences (2013- )

Member, Member Selection Committee of Global Network of Science Academies-IAP

(2013- )

Council Member of the Turkish Academy of Sciences (2015- )

EDUCATION

Medical School: Ankara University ,Medical School Ankara-Turkey. Degree: M.D. Date: 08/01/84

Research Associate, Chicago Medical School, North Chicago, Illinois (1988-1989)

Flow Cytometry and applications:

a) Prostate Cancer: (Chicago Medical School, Dept. of

Hematology and Oncology, Chicago, Illinois), USA (1989).

b) Mediterranean Lymphomas –IPSID: Medical College of

Wisconsin, Dept. of Hematology/Oncology, Milwaukee, Wisconsin,

4

4

USA (1990-1992).

Internship: Chicago Medical School (IL-USA) 1989-1990 Residency: Internal Medicine, Medical College of Wisconsin (WI-USA) 1990-1992 Fellowship:

Medical Oncology, The Fred Hutchinson Cancer Research Center, University of

Washington, School of Medicine, (Seattle USA) 1992 –1994.

Hematology and Bone Marrow Transplantation, The Fred Hutchinson Cancer

Research Center, University of Washington, School of Medicine, (Seattle USA)

1994-1996

Examinatiıons passed in the USA

Educational Commission for Foreign Medical Graduates (ECFMG)

23, 24 Temmuz 1986

Federal Licensing Examination (FLEX) 21, 22, 23 Haziran 1990

American College of Physicians Self - Assesment Examination (Aralık 1992)

American Board of Internal Medicine (ABIM) 15,16 Eylül 1993

American Board of Medical Oncology 21 Kasım 1997.

5

5

BOARD CERTIFICATIONS ECFMG Certificate: July 24, 1989 Federal License Examination (FLEX) (Part I-II) : June 20-22, 1990 Diplomate, American Board of Internal Medicine (ABIM): Sept. 21-22, 1993 Diplomate, American Board of Medical Oncology: November , 1997. Board eligible in Hematology

MEDICAL LICENSURE Washington State (USA) (Since 1992)

Wisconsin (USA) (Since 1989)

HONORS/AWARDS

Third Highest degree in class of 550. Univ. of Ankara, School of Medicine

(08/01/84)

Fellow of American College of Physicians (FACP), July 1996.

Outstanding Clinical Research Award, The Fred Hutchinson Cancer Research

Center, Seattle, WA, (April,1996)

ROCHE Hematology Award of Turkey October 1998

Junior Chamber of International (JCI) Award September 27, 2000

6

6

Science Award of The Scientific and Technical Research Council of Turkey, July

2002.

Science Award of The Bayındır Hospital Medical Center, 2004

Grand Honour Award of Turkish Parliament, 2014

CITATIONS

As of January, 2018, number of citations for publications cited in the Science

Citaton Index is 3965 and H value of 34 (ISI Web of Knowledge) and 37

(Scopus).

CONGRESS ACTIVITIES

Scientific Committee of the Second International High-Dose Chemotherapy Congress which was be held on April 9-12th 2002 in Banff, Canada.

President and Scientific Chairman of the EBMT annual meeting in March 2003 in Istanbul, Turkey. President of the (First, second, third and fourth) (2004-2007) National Medical Oncology Congress of Turkey President of the (First to sixth) Lymphoma-Myeloma Congress of Turkey (2009-2014)

Co-President of EBMT Annual Meeting in March 2015 in Istanbul, Turkey

7

7

INVITED SPEAKER OR CHAIRSHIPS IN INTERNATIONAL MEETINGS

1) ESH-EBMT Euroconference on Blood and Marrow Transplantation

(3-7 November 2001, Athens Greece)

Meet the Expert Session:

Speaker: Stem cell Transplantation in Patients with Solid Tumors (November 5,

2001).

2) 28th Annual Meeting of European Group for Blood and Marrow

Transplantation and 18th Meeting of Nurses Group (March 2002, Montreux,

Switzerland).

Speaker: Results of Breast Cancer Survey. Chairship: Solid Tumor Working

Party Session. (25-03-02, 15-17PM, Miles Davis Hall, Level-A3)

3) 28th Annual Meeting of European Group for Blood and Marrow

Transplantation and 18th Meeting of Nurses Group (March 2002, Montreux,

Switzerland). Chairship: Solid Tumor Working Party Oral Presentations. (26-03-

02, 13-15 PM, Leman A, Petit Palais)

4) Second International Conference on High Dose Chemotherapy-Innovation

and Evolution (April 9-12th 2002, Banff, Alberta, Canada)

Session I: High-Dose Chemotherapy (April 10, 2002)

Chairs: P. Stiff (USA), T. Demirer (Turkey)

Speaker: What’s going on in Europe (T. Demirer)

5) ‘IXth International Symposium on Biomedical Science & Technology ‘ (19-

22 Eylül 2002, Antalya, Turkey).

Speaker: CD34+ and Dendritic Cells in the field of Medical Oncology.

8

8

6) Second Euroconference and 5th workshop on clinical cytometry: From

pathogenesis to therapy (September 19-22, 2002 in Urbino).

Speaker: CD41+ and CD42+ hematopoietic progenitor cells as predictors of

platelet engraftment after stem cell transplantation.

7) Second International Congress on Advances in Hematology, Oncology

and BMT & First Nursing Meeting (September 25-29, 2002, Tehran, Iran).

Speaker: a) Autologus transplantation in solid tumors

Speaker: b) High-dose adjuvant chemotherapy in breast cancer.

8) Nuovi Standard Nella Prevenzione, Diagnosi E Cura in Oncologia

(Castelfranco Veneto, Italy 8-9 November, 2002).

Speaker: High-dose chemotherapy in solid tumors: European activity.

9) 3rd EBMT/AMGEN Workshop on Reduced Intensity Transplants (Zurich,

13-14 February, 2003.

Chairshipı: Reduced intensity transplants in olid tumors.

Introduction: Demographics in the Europe.

10) 29th Annual Meeting of European Group for Blood and Marrow

Transplantation and 19th Meeting of Nurses Group (March 23-26, 2003 in

Istanbul).

a) Chairship: (Schering-German Symposium on March 23rd) Reduced intensity

transplants.

b) Chairship (Novartis Symposium on March 23rd) CML, transplant and

Gleevec.

c) Chairship: Opening session (EBMT Lecture and Van Bekkum Award, March

23rd)

d) Chairship: Presidential symposium (March 24th).

9

9

e) Speaker: (Novartis Symposium on March 23, 2003): Imatinib or transplant-

Case studies

f) Speaker: Solid Tumors Working Party Session (March 24th)

g) Speaker: Role of stem cell transplantation in solid tumors-Ovarian cancer

(Educational Session, March 25th).

h) Chairship: GVT effects in the related and unrelated transplants in patients

with refractory solid tumors(March 26th).

11) ECCO-12, The European Cancer Conference (Copenhagen, 21-25

September 2003).

Speaker: Teaching Lecture: The status of bone marrow transplant clinical trials

(Monday, 22nd of September).

12) International workshop on high-dose chemotherapy in solid tumors

(Ravenna, Italy, 6-7 February 2004).

a) Chairship: High-dose chemotherapy in Breast cancer

b) Speaker: Summary of High-dose chemotherapy in solid Tumors.

13) Second Asian Pacific Bone marrow Transplantation Congress (Tehran,

Iran, Nov 18-20, 2004).

a) Speaker: Current status of High-dose chemotherapy and autologous stem

cell support in solid tumors (Nov 18, 2004).

b) Speaker: Nonmyeloablative stem cell transplantation in solid tumors (Nov 19,

2004)

10

10

14) 30th Annual Meeting of European Group for Blood and Marrow

Transplantation and 20th Meeting of Nurses Group (March 28-31, 2004 in

Barcelona).

a) Speaker and Chairship: Solid Tumors Working Party Session (March 29th,

2004)

b) Chairship: Transplantation in Solid Tumors (Workshop) (March 31st , 2004)

c)Speaker: Current Indications of Autologous Transplants (March 31st, 2004).

15) 31st Annual Meeting of European Group for Blood and Marrow

Transplantation and 21st Meeting of Nurses Group (March 20-23, 2005 in

Prague).

a) Speaker and Chairship: Solid Tumors Working Party Session (March 22th,

2005)

b) Speaker: (Educational Session) Stem cell mobilization: Factors influencing

stem cell collection (March 21st, 2005)

16) 15th Congress of the Interdisciplinary European Society for

Haemapheresis and Haematotherapy (ESFH). (October 6, 2005)

Speaker: Conference: Patients hard to mobilize in growth factors (45 minutes)

17) ECCO-13, The European Cancer Conference (Paris, October 30th-

November 3rd 2005).

a) Chairship: Non-myeloablative transplantation in solid tumors (November 2,

2005).

b) Speaker: Results in other solid tumors (November 2, 2005)

11

11

18) Second ATST Meeting-Allogeneic Transplantation in Solid Tumors,

Stresa, Italy, October 7-8, 2005.

Chairship: Graft-vs-Solid Tumor: Anectodal reports session

19) 32nd Annual meeting of the EBMT , March 19-22, 2006 in Hamburg,

Germany.

a) Chairship: Solid Tumor Working Party session (March 20, 2006)

b) Speaker: Introduction and Meta-analysis project for nreast cancer. (STWP

Session, March 20, 2006)

c) Speaker: (Educational session-6): Autologous transplantation in solid tumors

March 21, 2006)

20) The tenth ESH-EBMT training course on blood and marrow transplantation.

May 24-28, 2006, Hyatt Hotel, Warsaw, Poland.

a) Speaker: Autologous transplant in solid tumors. May 27, 2006.

21) 41st Annual meeting of the EBMT, March 2014 in Istanbul, Turkey.

a) Chairship: Solid tumors Working Part Session, March, 2014

b) Speaker: High-dose chemotherapy and ASCT in patients with ovarian cancer,

March 2014.

22) 18th International Pharmaceutical Technology Symposium. (18-09-16)

Session Chair: Clinical Trials and Future Perspectives

Speaker: A Review of Clinical Phase Studies and Current Problems in Turkey.

23) 2. Türkey-Azerbaijan Oncology Days (20-23 Ekim 2016, Bakü)

Topic: General Principles of Bone Marrow Transplantation (21-10-16).

12

12

MEMBER OF EDITORIAL REVIEW BOARD OF MAJOR JOURNALS 1) Bone Marrow Transplantatıon (1998-2014). 2) Stem Cells and Development (1999-2012) 3) World Journal of Hematology (2015- )

PROFESSIONAL MEMBERSHIPS AND SOCIETIES American College of Physicians (ACP) American Society of Clinical Oncology (ASCO) The American Society of Hematology (ASH) The American Society for Blood and Marrow Transplantation (ASBMT) Wisconsin Medical Society (Wisconsin-USA) Milwaukee County Medical Society (Wisconsin USA) Washington State Medical Society (Seattle-USA) European Bone Marrow Transplantation (EBMT) European Hematology Association (EHA) European Society of Medical Oncology (ESMO) Turkish Society of Hematology Turkish Society of Clinical Oncology

13

13

RESEARCH INTERESTS 1) High dose chemotherapy with recombinant human growth factors for

cytoreduction and peripheral blood stem cell mobilization.

2) High dose chemotherapy followed by autologous stem cell rescue for treatment of

ovarian, breast, testicular and small cell lung cancer.

3) Autologous stem cell transplantation using peripheral blood stem cells in patient

with multiple myeloma, lymphoma and acute myelogenous leukemias.

4) Allogeneic stem cell transplantation with reduced intensity regimens in patients

with refractory solid tumors.

5) Allogeneic peripheral blood stem cell transplantation in patients with hematologic

malignancies.

CONDUCTED STUDIES

I) Studies Chaired or Co-Chaired by Dr. DEMIRER at the Fred

Hutchinson Cancer Research Center, Previously (1992-1997).

Granulocyte-colony stimulating factor (G-CSF) alone for peripheral blood stem

cell (PBSC) mobilization in patients with hematologic malignancies.

Chemotherapy based regimens for cytoreduction and PBSC mobilization in

patients with lymphoma, breast and ovarian cancer.

14

14

Cyclophosphamide, paclitaxel and rhG-CSF for cytoreduction and PBSC

mobilization in patients with breast and ovarian cancer.

Busulfan and cyclophosphamide as a conditioning regimen in patients with

breast cancer.

Phase-II study of High-dose chemotherapy with busulfan, melphalan and

thiotepa followed by autologous stem cell rescue in patients with advanced stage

ovarian cancer.

Phase I-II trial of allogeneic marrow transplantation following cyclophosphamide

and escalating doses of hyper-fractionated total body irradiation in patients with

advanced lymphoid malignancies.

Phase-I dose escalation of busulfan based on targeted plasma levels: Busulfan,

cyclophosphamide and fractionated total body irradiation for allogeneic marrow

transplantation for advanced acute and chronic myelogenous leukemia.

Phase-I dose escalation of busulfan based on targeted plasma levels: Busulfan,

cyclophosphamide and fractionated total body irradiation for autologous or

syngeneic marrow transplantation for advanced acute and chronic myelogenous

leukemia.

High-dose therapy followed by autologous hematopoietic stem cell infusion for

patients with multiple myeloma.

Autologous marrow and/or PBSC transplantation in patients with acute

myelogenous leukemia: Engraftment characteristics and the incidence of relapse

with PBSCs.

15

15

Allogeneic peripheral blood stem cell mobilization and transplantation in patients

with advanced hematological malignancies.

II) Studies Chaired or Co-Chaired by Dr. DEMIRER as chairman of the

EBMT Solid Tumors Working Party, (2001-2007).

A randomised study IT94 in relapsing germ cell tumours including patients in

incomplete remission.

Chairman: Taner Demirer (Ankara-Turkey), Principal İnvestigator: JL Pico, Bone

Marrow Transplantation Unit,Hematology Division, Institut Gustave Roussy, Rue

Camille Desmoulins, 94805 Villejuif Cedex, FRANCE

Randomised study (Random-ICE) EBMT phase-III randomized trial for small cell

lung cancer (started June 1997, Completed in 2004)

Chairman: Taner Demirer (Ankara-Turkey), Principal İnvestigator: Serge

Leyvraz, Centre Pluridisciplinaire d'Oncologie, Rue de Bugnon 26 CHUV-10,

1011 Lausanne, SWITZERLAND.

A phase III randomised study on advanced ovarian carcinoma started in April

1998 (OVCAT Study) and completed in 2004.

Chairman: Taner Demirer (Ankara-Turkey), Principal İnvestigator: J Ledermann,

Department of Oncology, University College London Medical School, 91 Riding

House Street, London W1P 8BT, UNITED KINGDOM.

PEGASE 03 High-dose cyclosphosphamide and Thiotepa after FEC for metastatic disease versus FEC alone

16

16

Chairman: Taner Demirer (Ankara-Turkey), Principal İnvestigator: P Biron,

Centre Leon Berard,Rue Laennec 28 ,69373 Lyon Cedex 08, FRANCE

PEGASE 05 A new phase 2 study on non metastatic inflammatory breast cancer

Chairman: Taner Demirer (Ankara-Turkey), Principal İnvestigator: P Viens,

Institute Paoli l. Calmettes, 232 Boulevard de Ste. Marguerite, 13273 Marseille

Cedex 9, FRANCE.

Phase I study on the role of allografting in solid tumours

Chairman: Taner Demirer (Ankara-Turkey), Principal İnvestigator: D

Niederwieser, Klinik für Innere Medizin, Abt. Hematologie/Onkologie, Universitat

Leipzig, Johannisallee 32, D-7010 Leipzig, Germany.

A randomised phase 3 study on relapsed platinum sensitive epithelial ovarian

cancer (Closed).

Chairman and Principal İnvestigator: T Demirer, Ankara University Medical

School, Ibn-i Sina Hospital, EBMT Office, Floor 05, Sihhiye, 06100 Ankara,

Turkey.

A randomised phase 3 study on completely responding metastatic breast cancer.

A joint protocol of the EBMT and MDACC. Chairman: T. Demirer (Ankara-

Turkey), Principal investigators: G. Hortobagyi, MDACC, Texas, USA ; N. Ueno,

MDACC, Texas, USA; and T. Demirer (Ankara-Turkey).

A randomised phase 3 study on partially responding metastatic breast cancer. A

joint protocol of the EBMT and GITMO.

Chairman: T. Demirer (Ankara-Turkey), Principal investigators: M. Aglietta and F.

Montemurro, Turin, Italy.

17

17

Phase-II randomized study of intra-familial allogeneic stem cell transplantation

for patients suffering from metastatic renal cell carcinoma. A joint protocol of the

EBMT and French National Group. Chairman: T. Demirer (Ankara-Turkey),

Principal investigator: D. Blaise (Marseille, France).

III) RETROSPECTIVE studies coordinated by Dr. Demirer in related

to autologous stem cell transplantation as chairman of the EBMT

STWP:

i) EBMT retrospective study on female germ cell tumors

Study chair: Dr. Luca Castagna

E-mail:luca.castagna@humanitas.it

ii) EBMT retrospective study on soft tissue sarcoma

Study chair: Dr. Peter Reichardt

E-mail:peter.reichardt@charıte.de

iii) EBMT retrospective study on Osteosarcoma

Study chair: Dr. Jeremy Whelan

E-mail: jeremy.whelan@uclh.org

iv) EBMT retrospective study on Ovarian Carcinoma patients CR1 at graft

Study chair: Dr. Carmelo Bengala

E-mail: c.bengala@do.med.unipi.it

v) Retrospective study on Neuroblastoma

Study chair: Dr. Frederique Rousseau

E-mail: frederique.rousseau@ch-pontoise.fr

vi) Retrospective study on Ewing`s Sarcoma and PNET

Study chair: Dr. Amelia Tienghi and Alexia Bertuzzi

E-mail: atienghi@libero.it

vii) Retrospective study on Astrocytoma

Study chair: Dr. Olivier Bay

18

18

E-mail: olivier.bay@cjp.u-clermont1.fr

viii) Retrospective study on Medulloblastoma

Study chair: Dr. Paolo Pedrazzoli

E-mail: pedraz@tin.it

ix) Retrospective study on Melanoma

Study chair: Dr. Bernd Hertenstein (not confirmed)

E-mail: Hertenstein.Bernd@mh-hannover.de

x) Retrospective study on Thymoma(not confirmed)

Study chair: Dr. Didier Blaise

E-mail: uttc@marseille.fnclcc.fr

xi) Retrospective study on Gastric Carcinoma

Study chair: Dr. Reinhard Adreesen

E-mail: reinhard.andreesen@klinik.uni-regensburg.de

xii) Retrospective study on Small Cell Lung Cancer

Study chair: Dr. Giovanni Rosti, Dr. Ugo De Giorgi

E-mail: rosti@ra.nettuno.it , ugo_degiori@yahoo.com

XIII) Retrospective study on Non Small Cell Lung Cancer(not confirmed)

Study chair: Dr. Giovanni Rosti, Dr. Ugo De Giorgi

E-mail: rosti@ra.nettuno.it , ugo_degiori@yahoo.com

xiii) Retrospective study on Unknown Origin Adenocarcinoma

Study chair: Dr. Fikret Arpaci

E-mail: farpaci@gata.edu.tr

xiv) Retrospective study on Wilms` tumors

Study chair: Dr. Emel Unal

E-mail: eunal@superonline.com

xv) Retrospective study on Inflammatory Breast cancer

Study chair: Dr. Ugo De Giorgi

E-mail: ugo_degiori@yahoo.com

19

19

IV) Meta-analysis project in breast cancer- An international task

force on behalf of the EBMT Solid Tumor Working Party

Demirer T (Chairman) Project Coordinator (Turkey)

Berry A.D, PhD, USA, (American Principal Investigator)

This project was a joint venture of EBMT and MDACC under

coordinatorship of Professor Demirer, chairman of the EBMT STWP

(2001-2007). It started in 2007 and completed in 2010. All prospective

radomized trails investigating the efficacy of high-dose chemotherapy

(HDC) and autologous stem cell transplant(ASCT) in patients with

breast cancer in the adjuvant and metastatic settings were included in

this meta-analysis. Data of 15 trials in the adjuvant and 6 trials in the

metastatic setting done worldwide have been accumulated at the dept,

of Statistics of MDACC in Houston, Texas. Results of this meta-

analysis were published in the Journal of Clinical Oncology as 2

consecutive manuscripts in 2011. Results of this meta-analysis has

shed a valuable light on this issue. Based on this analysis HDC and

ASCT showed statistically significant progression free survival

advantage in both adjuvant and metastatic settings compared to

conventional chemotherapy. But there was no overall survival

advantage in both groups. Furthermore, advantage of HDC and ASCT

in some subgroup of breast cancer patients were defined and a new

randomized trial was kicked off in Netherland, in 2012, targeting the

patients with triple negative and BRCA-1 like disease.

20

20

V) RETROSPECTIVE studies coordinated by Dr. Demirer in related to

allogeneic stem cell transplantation in solid tumors as chairman of

the EBMT STWP:

i) Retrospective analysis of EBMT allograft in renal cancer

Study chair: Lisbeth Barkholt

E-mail: lisbeth.barkholt@transpl.hs.sll.se

ii) Prognostic factors in EBMT renal cancer experience

Study chair: Jacopo Peccatori

E-mail: peccatori.jacopo@hsr.it

iii) Retrospective analysis of EBMT/IBMTR experience of allograft in breast cancer

Study chair: Dietger Niederwieser

E-mail:dietger@medizin.uni-leipzig.de

iv) Retrospective analysis of EBMT allograft in ovarian cancer

Study chair: Olivier Bay

E-mail: olivier.bay@cjp.u-clermont1.fr

v) Retrospective analysis of EBMT colorectal cancers

Study chair: Massimo Aglietta

E-mail: massimo.aglietta@ircc.it

vi) Nonmyeloablative transplants in soft tissue sarcomas

Study chair: Paolo Corradini

E-mail: paolo.corradini@istitutotumori.mi.it

vii) Histopathology of renal cell cancer and patient survival after allogeneic SCT

Study chair: Lisbeth Barkholt, E-mail: lisbeth.barkholt@transpl.hs.sll.se

21

21

VI) Studies chaired or co-chaired by Dr. DEMIRER in Turkey.

Phase-I dose escalation study of high-dose thiotepa, melphalan and carboplatin

(TMCb) followed by autologous peripheral blood stem cell transplantation in

patients with solid tumors and hematologic malignancies.

Epirubicin, carboplatin and paclitaxel versus Carboplatin and paclitaxel in

patients with de novo epithelial ovarian cancer: Phase IV randomized study.

Phase-II study of high-dose thiotepa, melphalan and carboplatin (TMCb)

followed by autologous peripheral blood stem cell transplantation in patients with

solid tumors and hematological malignancies.

Randomized phase-III trial of interferon administration following high-dose

chemotherapy and autologous peripheral blood stem cell transplantation in

patients with multiple myeloma (Multi-center study started in 2002).

Randomized study of rhG-CSF administration starting on day 0 and day 5 versus

none in patients with solid tumors following high-dose chemotherapy and

autologous stem cell transplantation.

22

22

PUBLICATIONS

Taner Demirer, MD, FACP

1. Demirer T, Icli F, Uzunalimoglu O, Kucuk O: Diet and Stomach Cancer

Incidence. A case control study in Turkey. "CANCER", Vol:65, No:10, pp:2344-

2348,1990.

2. Kucuk O, Demirer T, Gilman-sachs, Taw I, Mangold M, Singh S and Westerman

M P: Intratumor heterogeneity of DNA ploidy and correlations with clinical stage and

histologic grade in prostate cancer. "JOURNAL of SURGICAL ONCOLOGY" Vol:54,

pp:171-174, 1993.

3. Demirer T, Dail D, and Aboulafia D : Four varied cases of intravascular

lymphomatosis. "CANCER", March 15, Volume 73, No.6, pp: 1738-1745, 1994.

4. Bensinger W, Demirer T, and Buckner C.D: Factors influencing stem cell

mobilization and engraftment kinetics after transplantation of peripheral blood stem

cells (PBSC's). Recent advances in hematopoietic stem cell transplantation-

clinical progress, new technologies and gene therapy. University of California, San

Diego School of Medicine. Meeting Report, pp: 109-116, March 10-12, 1994.

5. Demirer T, Buckner C.D, Lilleby K, Weaver CH, Longin K, Appelbaum F,

Bensinger W: Failure of a single cycle of high dose cyclophosphamide followed by

intensive myeloablative therapy and autologous stem cell transplantation to improve

outcome in relapsed disease. "CANCER" Vol:74, no.2, pp:715-721,1994.

23

23

6. Demirer T, Ravits J, Aboulafia D: Lambert-Eaton Myasthenic Syndrome

associated with pulmonary large cell neuroendocrine carcinoma. "SOUTHERN

MEDICAL JOURNAL", Vol:87, No:11, pp:1186-1189,1994.

7. Demirer T, Uzunalimoglu O, Koethe S, Kucuk O, McFadden W.P, Uzunalimoglu

B, Anderson T: Flow cytometric measurement of proliferation-associated nuclear

antigen P105 and DNA content in immuno-proliferative small intestinal disease.

"JOURNAL OF SURGICAL ONCOLOGY", Vol:58, No:1, pp:25-30, (January), 1995.

8. Aboulafia D, Demirer T: Diffuse Myelonecrosis following Fludarabin

administration in a patient with indolent lymphoma. "LEUKEMIA & LYMPHOMA", vol:

19, pp:181-184, 1995.

9. Demirer T, Weaver CH, Buckner CD, Petersen FB, Bensinger WI, Sanders J,

Clift RA, Anasetti C, Martin P, Storb R, Appelbaum FR: High-dose cyclophosphamide,

carmustine, and etoposide (CBV) followed by allogeneic bone marrow transplantation in

patients with lymphoid malignancies who had received dose-limiting radiation therapy.

"JOURNAL of CLINICAL ONCOLOGY", Vol:13, No:3 (March), page:596-602, 1995.

10. Bensinger W.I, Weaver C.H, Appelbaum F.R, Rowley S, Demirer T, Sanders

J.E, Storb R, Buckner C.D. Transplantation of allogeneic peripheral blood stem cells

mobilized by recombinant human granulocyte colony stimulating factor (rhG-CSF).

"BLOOD", Vol:85, No:6, pages:1655-1658, 1995.

11. Demirer T, Buckner C.D, Petersen F.B, Appelbaum F, Rowley S, Sanders J,

Storb R, Benyunes MC, Fefer A, and Bensinger W. et al: Rapid engraftment after

autologous transplantation utilizing marrow and recombinant granulocyte-colony

stimulating factor (G-CSF) mobilized peripheral blood stem cells in patients with acute

myelogenous leukemia. "BONE MARROW TRANSPLANTATION", Vol:15, No:6,

24

24

pp:915-922, June 1995.

12. Demirer T, Bensinger WI. Optimization of peripheral blood stem cell collections.

"CURRENT OPINION in HEMATOLOGY", Vol:2, No:3, pages:219-226, 1995.

13. Demirer T, Gooley T, Buckner CD, Petersen FB, Lilleby K, Rowley S, Sanders J,

Storb R, Appelbaum FR, Bensinger WI: The influence of total nucleated cell dose from

marrow harvests on outcome in patients with acute myelogenous leukemia undergoing

autologous transplantation. "BONE MARROW TRANSPLANTATION", Vol:15, No:6,

pp:907-913, June 1995.

14. Demirer T, Petersen F.B, Appelbaum F.R, Sanders J.E, Deeg J, Storb R, Doney

K, Bensinger W.I, Shannon-Dorcy K. and Buckner C.D. Allogeneic marrow

transplantation following cyclophosphamide and escalating doses of hyper-fractionated

total body irradiation in patients with advanced lymphoid malignancies-A phase I-II trial.

"INTERNATIONAL J of RADIAT ONCOL BIOL. PHYS" Vol:32, No:4, pp:1103-1109,

1995.

15. Demirer T, Rowley S, Buckner C.D, Appelbaum F.R., Lilleby K, Storb R,

Bensinger W.I. Peripheral blood stem cell (PBSC) collections after paclitaxel,

cyclophosphamide and recombinant human granulocyte-colony stimulating factor in

patients with breast and ovarian cancer. "JOURNAL OF CLINICAL ONCOLOGY",

Vol:13, No:7, pp:1714-1719, July 1995.

16. Bensinger WI, Appelbaum F, Rowley S, Storb R, Sanders J, Gooley T, Demirer

T, Schiffman K, Weaver C, Clift R, Chauncey T, Klarnet J, Montgomery P, Petersdorf S,

Weiden P, Witherspoon R, and Buckner CD: Factors that influence collection and

engraftment of autologous peripheral blood stem cells. "JOURNAL OF CLINICAL

ONCOLOGY" Vol:13, No:10, pp:2547-2555, October 1995.

25

25

17. Bensinger WI, Demirer T, Rowley S, Buckner CD: Factors predictive of rapid

engraftment after peripheral blood stem cell infusions. "BONE MARROW

TRANSPLANTATION" Vol:15, Suppl:3, pages: 83-85, 1995.

18. Bensinger WI, Clift RA, Anasetti C, Appelbaum FR, Demirer T, Rowley S,

Sandmaier BM, Torok-Storb B, Storb R, and Buckner CD: Transplantation of

allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte-

colony stimulating factor. "STEM CELLS" Vol:14, No:1, pages:90-105, 1996.

19. Demirer T, Buckner CD, Bensinger WI: Optimization of peripheral blood stem

cell mobilization. "STEM CELLS" Vol:14, No:1, pages:106-116, 1996.

20. Bensinger WI, Buckner CD, Rowley S, Demirer T, Storb R, and Appelbaum FR.

Transplantation of allogeneic CD34+ peripheral blood stem cells (PBSC) in patients

with advanced hematologic malignancy. ‘BONE MARROW TRANSPLANTATION’

Vol:17 (Suppl.2): S 38-39, 1996.

21. Bensinger WI, Buckner CD, Demirer T, Storb R, Appelbaum FR.

Transplantation of allogeneic peripheral blood stem cells, Proceedings of the First

ınternational Symposium on Allogeneic Peripheral Blood Progenitor Cell

Transplantation, An EBMT Symposium. ‘BONE MARROW TRANSPLANTATION’

Vol:17 (Suppl.2): S56-S57, 1996.

22. Demirer T, Buckner CD, Appelbaum FR, Lambert K, Bensinger WI, Clift R, Storb

R, Slattery JT: Busulfan, cyclophosphamide and fractionated total body irradiation for

allogeneic marrow transplantation for advanced acute and chronic myelogenous

leukemia: Phase I dose escalation of busulfan based on targeted plasma levels. ‘BONE

MARROW TRANSPLANTATION" Vol:17, pages:341-346, 1996.

26

26

23. Demirer T, Buckner CD, Appelbaum FR, Clift R, Storb R, Myerson D, Lilleby K,

Rowley S, Bensinger WI: High-dose busulfan and cyclophosphamide followed by

autologous transplantation in patients with advanced breast cancer. "BONE

MARROW TRANSPLANTATION", Vol:17, pp:769-774, 1996.

24. Demirer T, Buckner CD, Appelbaum FR, Bensinger WI, Sanders J, Lambert K,

Clift R, Fefer A, Storb R, Slattery JT: Busulfan, cyclophosphamide and fractionated total

body irradiation for autologous or syngeneic marrow transplantation for acute and

chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted

plasma levels. "BONE MARROW TRANSPLANTATION", Vol: 17, pp:491-495, 1996.

25. Schiffman K, Bensinger WI, Appelbaum FR, Rowley S, Lilleby K, Clift R, Weaver

CH, Demirer T, Sanders J, Petersdorf S, Gooley T, Weiden P, Zuckerman N,

Montgomery P, Maziarz R, Klarnet JP, Trueblood K, Storb R, Buckner CD: Phase II

study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood

stem cell support in patients with malignant disease. "BONE MARROW

TRANSPLANTATION", Vol: 17, pp:943-950, 1996.

26. Bensinger WI, Appelbaum FR, Demirer T, Torok-Storb B, Storb B, Buckner CD:

Transplantation of allogeneic peripheral blood stem cells. "STEM CELLS" Vol:13

(Suppl 3), pp 63-70, 1995.

27. Brunvand MW, Appelbaum FR, Soll E, Lilleby K, Clift R, Gooley T, Bensinger WI,

Weaver CH, Rowley SD, Fefer A, Press OW, Storb R, Sanders J, Martin PL, Chauncey

T, Maziarz RT, Weiden P, Demirer T, Holmberg LA, Schiffman K, McSweeney PA,

Maloney DG, Buckner CD: High-dose fractionated total-body irradiation, etoposide and

cyclophosphamide for treatment of malignant lymphoma: Comparison of autologous

bone marrow and peripheral blood stem cells. "BONE MARROW

TRANSPLANTATION", Vol:18, pp: 131-141, 1996.

27

27

28. Bensinger WI, Rowley SD, Demirer T, Appelbaum FR, Lilleby K, Schiffman K,

Clift RA, Barnett T, Storb R, Chauncey T, Maziarz RT, Klarnet J, Gooley TA, Fefer A,

McSweeney PA, Holmberg L, Maloney DG, Weaver CH, Buckner CD: High-dose

therapy followed by autologous hematopoietic stem cell infusion for patients with

multiple myeloma. "JOURNAL OF CLINICAL ONCOLOGY", Vol:14, No:5, pp:1447-

1456, 1996.

29. Demirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T,

Lilleby K, Storb R, Bensinger WI: Factors influencing collection of peripheral blood

stem cells in patients with multiple myeloma. "BONE MARROW

TRANSPLANTATION", Vol:17, pp:937-941, 1996.

30. Demirer T, Petersen FB, Bensinger WI, Appelbaum FR, Fefer A, Rowley S,

Sanders J, Chauncey T, Storb R, Lilleby K, Buckner CD: Autologous transplantation

with peripheral blood stem cells collected after granulocyte-colony stimulating factor in

patients with acute myelogenous leukemia. "BONE MARROW TRANSPLANTATION",

Vol: 18, pp:29-34, 1996.

31. Bensinger WI, Demirer T, Buckner CD, Appelbaum FR, Storb R, Lilleby K,

Weiden P, Bluming AZ, Fefer A: Syngeneic marrow transplantation in patients with

multiple myeloma. "BONE MARROW TRANSPLANTATION", Vol:18, pp. 527-531,

1996.

32. Demirer T: Taxol with cyclophosphamide improves stem cell collection for

autologous use. "NATIONAL CANCER BULLETIN", pp:1-3, January-February, 1996.

28

28

33. Bensinger WI, Clift R, Martin P, Demirer T, Sanders J, Buckner CD: Allogeneic

peripheral blood stem cell transplantation in patients with advanced hematologic

malignancies: A retrospective comparison with marrow transplantation. ‘BLOOD’, Vol:

88, No:7, pp: 2794-2800, 1996.

34. Bensinger WI, Buckner CD, Shannon-Dorcy K, Rowley S, Appelbaum FR,

Benyunes M, CliftR, Mason P, Demirer T, Storb R, Lee M, Schiller G: Transplantation

of allogeneic CD34+ peripheral blood stem cells (PBSC) in patients with advanced

hematologic malignancy. BLOOD, Vol:88, No:11, pp:4132-4138, 1996.

35. Demirer T, Buckner CD, Storer B, Appelbaum FR, Storb R, Bensinger WI: The

effect of different chemotherapy regimens on peripheral blood stem cell mobilization

yield. ’JOURNAL OF CLINICAL ONCOLOGY’, Vol 15, No:2, pp:684-690,1997.

36. Bensinger W.I, Weaver C.H, Appelbaum F.R, Rowley S, Demirer T, Sanders

J.E, Storb R, Buckner C.D. Hot Papers-Transplantation of allogeneic peripheral blood

stem cells mobilized by recombinant human granulocyte colony stimulating factor . ’

THE SCIENTIST ’ vol:11, No:2, pp 15-16, 1997

37. Williams O, Demirer T, Lilleby K, Buckner CD, Bensinger WI. Tempo of

hematologic recovery correlates with peripheral blood CD34+ cell level in patients

undergoing stem cell mobilization. J. CLIN APHERESIS Vol:13, pp1-6, 1998.

38. Dilek I, Demirer T, Üstün C, Arat M, Koç H, Beksaç M, Erdi H, Anadolu R, Özcan

M, İlhan O, Akan H: Acquired icthyosis associated with chronic graft-versus-host

disease following an allogeneic peripheral blood stem cell transplantation in a patient

with chronic myelogenous leukemia. ‘BONE MARROW TRANSPLANTATION’ Vol:21,

pp: 1159-1161, 1998

29

29

39. Dilek İ, Uysal A, Demirer T, Koç H, Özcan M, Keleş H, Numanoğlu N, Üstün C,

Çiftçi E: Acute myeloblastic leukemia associated with hyperleukocytosis and diabetes

insipidus. ‘LEUKEMİA and LYMPHOMA’ Vol:30, pp: 657-660, 1998.

40. Holmberg LA, Demirer T, Rowley S, Buckner CD, Goodman G, Maziarz R,

Klarnet J, Zuckerman N, Harrer G, McCloskey R, Goldberg R, Nichols W, Jacobs A,

Weiden P, Montgomery P, Rivkin S, Appelbaum FR, Bensinger WI: High-dose

busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell

(PBSC) rescue in patients with advanced stage III-IV ovarian cancer. ‘BONE

MARROW TRANSPLANTATION’, Vol: 22, pp 651-659, 1998.

41. Üstün C, Arslan Ö, Beksaç M, Koç H, Gürman G, Özçelik T, Yılmaz B, İlhan O,

Akan H, Özcan M, Demirer T, Uysal A, Konuk N, Arat M, Dilek İ, Çelebi H, Şenol C: A

retrospective comparison of allogeneic peripheral blood stem cell and bone marrow

transplantation results from a single center, a focus on the incidence of GVHD and

relapse. ‘BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION’, Vol:5, pp 28-

35, 1999.

42. Demirer T, Bensinger WI, Buckner CD: Peripheral Blood stem cell mobilization

for high dose chemotherapy. ‘JOURNAL OF HEMATOTHERAPY’, Vol:8, pp 103-113,

1999.

43. Demirer T, Çelebi H, Arat M, Üstün C, Demirer S, Dilek İ, Özcan M, Ilhan O,

Akan H, Gürman G, Koç H: Autoimmune thrombocytopenia in a patient with small cell

lung cancer developing after chemotherapy and resolving following autologous

peripheral blood stem cell transplantation. ‘BONE MARROW TRANSPLANTATION’,

Vol:24, pp 335-337, 1999.

30

30

44. Üstün C, Çelebi H, Arat M, Özcan M, Dilek İ, Gürman G, Demirer T, İlhan O,

Keskin R, and Koç H. Treatment of aregeneratoric anemia following an ABO-

incompatible allogeneic peripheral blood stem cell transplantation: A case report.

‘THERAPEUTIC APHERESIS’ Vol:3, No:3, pp 275-277, 1999.

45. Rosti G, Ferrante P, Crown J, Pıco JL, Leyvraz S, Ledermann J, Demirer T,

Carıello A, Gıovanis P. High-dose chemotherapy and autologous stem cell

transplantation in patients with breast cancer and other solid tumors. A review of the

EBMT data.’TURKISH JOURNAL OF HEMATOLOGY’, Vol:16, No:3, pp. 19-26,

(Suppl), 1999.

46. Demirer T, Arat M, Koç H, Üstün C, Özcan M, Gürman G, Arslan Ö, Çelebi H,

İlhan O. Stem cell mobilization with cyclophosphamide, paclitaxel (or etoposide) and

recombinant granulocytecolony stimülating factor (rhG-CSF): Ibn-I Sina experience.

’TURKISH JOURNAL OF HEMATOLOGY’, Vol:16, No:3, pp. 83-84, (Suppl), 1999.

47. Demirer T, Çelebi H, Akçağlayan E, Üstün C, Demirer S, Ekinci C, Bahar K, Koç

H. An interesting clinical picture of immünoproliferatif small intestinal disease (IPSID):

Dıagnosis in oncology. ‘JOURNAL OF CLINICAL ONCOLOGY’ Vol:17, No:11, pp

3682-3684, 1999.

48. Üstün C, Özcan M, Gürman G, Çakır M, Erekul S, Akyol G, Arat M, Çelebi H,

İdilman R, Akan H, İlhan O, Demirer T, Beksaç M, Koç H: Differences in liver

pathology and clinical outcomebetween two patients with hepatitis B virus and graft

versus host disease. Pathology & Oncology Research, Vol:5, No:3, pp 229-232,

1999.

31

31

49. Demirer T, Ilhan O, Mandel NM, Arat M, Günel N, Çelebi H, Üstün C, Akan H,

Uysal A, Koç H: A phase-I dose escalation study of high-dose thiotepa, melphalan and

carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation

(PBSCT) in patients with solid tumors and hematologic malignancies. ‘BONE

MARROW TRANSPLANTATION’ Vol: 25, pp 697-703, 2000.

50. Arslan Ö, Coşkun Ş, Arat M, Çelebi H, Özcan M, Gürman G, Demirer T, Akan H,

İlhan O, Konuk N, Beksaç M, Uysal A, Koç H: Four years experience of Ibn-i Sina

Hospital in allogeneic peripheral blood stem cell transplantation for standard risk

leukemias. ‘ BONE MARROW TRANSPLANTATION’ Vol: 25, pp 1229-1232, 2000.

51. Demirer S, Aydıntuğ S, Üstün C, Tüzün A, Başaran Ö, Türkmen E, Coşkun Ş,

Çelebi H, Demirer T: Comparison of the efficacy of medium chain triglycerides with

long chain triglycerides in TPN patients with hematologic malignancies undergoing

hematopoietic peripheral blood stem cell transplantation. CLINICAL NUTRITION, Vol:

19, No: 4, pp 253-258, 2000.

52. Demirer T, O. Ilhan, M. Arat, K. Dalva, M. Beksaç, H. Çelebi, C. Üstün, H. Akan,

M. Özcan, G. Gürman, N. Konuk, A. Uysal, H. Koç: CD41+ and CD42+ hematopoietic

progenitor cells predict platelet engraftment after allogeneic peripheral blood stem cell

transplantation. JOURNAL OF CLINICAL APHERESIS, Vol: 16, pp 67-73, 2001.

53. Özcan M, Üstün C, Akçağlayan E, Akan H, Arslan Ö, İlhan O, Beksaç M,

Gürman G, Demirer T, Arat M, Çelebi H, Konuk N, Uysal A, Koç H. Recombinant

human granulocyte colony-stimulating factor(rhG-CSF) may accelerate hematopoietic

recovery after HLA identical sibling allogeneic peripheral blood stem cell

transplantation. BONE MARROW TRANSPLANTATION, Vol:27, pp 499-505, 2001.

32

32

54. Arat M, Ulusoy FV, Demirer T et al. Three cases of pericardial involvement of

multiple myeloma. LEUKEMIA & LYMPHOMA, Vol: 43, Pp 145-148, 2002.

55. Demirer T, Aylı M, Ozcan M, Gunel N, Haznedar R, Dağlı M, Fen T, Genc Y,

Dincer S, Arslan O, Gürman G, Demirer S, Özet G, Uysal A, Konuk N, İlhan O, Koc

H, Akan H: Mobilization of peripheral blood stem cells with chemotherapy and

recombinant human granulocyte-colony stimulating factor (Rh-GSCF): A randomized

evaluation of different doses of Rh-GSCF. BRITISH JOURNAL OF HAEMATOLOGY,

Vol: 116, pp 468-472, 2002.

56. Demirer T, Daglı M, Ilhan O, Aylı M, Haznedar R, Fen T, Günel N, Genc Y, Arat

M, Ozcan M, Arslan Ö, Seyrek E, Dincer S, Üstün T, Ustael N, Koc H, Müftüoğlu O,

Akan H. A randomized trial of assessment of efficacy of leukapheresis volumes, 8 liters

vs 12 liters. BONE MARROW TRANSPLANTATION, Vol: 29, pp 893-897, 2002.

57. Arslan O, Coşkun HŞ, Arat M, Soydan E, Özcan M, Gürman G, Çelebi H,

Demirer T, Akan H, Ilhan O, Konuk N, Uysal A, Beksac M, Koc H. The role of ABO

incompatibility in allogeneic peripheral blood stem cell transplantation. TURK J

HAEMATOL, Vol: 19(3):401-409, 2002.

58. Demirer T, İlhan O, Aylı M, Arat M, Daglı M, Özcan M , Haznedar R, Genç Y,

Fen T, Ayyılldız E, Dincer S, Arslan Ö, Gürman G, Konuk N, Dalva K, Uysal A, Koç H,

Özet G, Akan H. Monitoring of peripheral blood CD34+ cell counts on the first day of

apheresis is highly predictive for efficient CD34+ cell yield. THERAPEUTIC

APHERESIS, Vol: 6 (5), pp 384-389, 2002.

33

33

59. Demirer T, Aylı M, Daglı M, Haznedar R, Genc Y, Fen T, Dincer S, Ünal E,

Günel N, Seyrek E, Üstün T, Ustael N, Yıldız M, Sertkaya D, Ozet G, Müftüoğlu O.

Influence of post-transplant recombinant human granulocyte-colony stimulating factor

administration on peritransplant morbidity in patients undergoing autologous stem cell

transplantation. BRITISH JOURNAL OF HAEMATOLOGY, Vol:118, pp 1104-1111,

2002.

60. Demirer T, Aylı M, Daglı M, Fen T, Haznedar R, Ustael N, Ustun T, Oymak A,

Ozdel O, Müftüoğlu O. The effect of post-transplant spironolactone on daily potassium

requirements in patients undergoing autologous stem cell transplantation. BONE

MARROW TRANSPLANTATION, Vol: 30, pp 703-706, 2002.

61. Daglı M, Demirer T, Aylı M, Haznedar R, Günel N, Sucak G, Fen T, Moran M,

Üstün T, Aybirdi C, Çavuşoglu M, Dincer S, Uysal A. Plasmacytoma in the bilateral

breast. TURK J HAEMATOL, Vol: 19 (4): 477-480, 2002.

62. Kröger N, Zander AR, Martinelli G, Ferrante P, Moraleda JM, Da Prada GA,

Demirer T, Socie G, Rosti G on behalf of the Solid Tumors Working Party of the

European Group for Blood and Marrow Transplantation. Low incidence of secondary

myelodysplasia and acute myeloid leukemia after high dose chemotherapy as adjuvant

therapy for breast cancer patients: a study by the Solid Tumors Working Party of the

European Group for Blood and Marrow Transplantation. ANNALS OF ONCOLOGY

14:554-558,2003.

63. Demirer T, Uysal VA, Aylı M, Genc Y, Ilhan O, Koc H, Daglı M, Arat M, Gunel N,

Fen T, Dincer S, Ustael N, Yıldız M, Ustun T, Seyrek E, Ozet G, Muftuglu O, Akan H.

High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem

cell transplantation in patients with advanced breast cancer: a retrospective evaluation.

BONE MARROW TRANSPLANTATION, Vol:31, 755-761, 2003.

34

34

64. Demirer T .(Book Chapter). CD 34+ Cells in Hematopoietic Stem Cell

Transplantation. Chapter 8, pp 107-118. In TISSUE ENGINEERING, STEM CELLS,

AND GENE THERAPIES. (Advances in Experimental Mmedicine and Biology,

Volume 534). Edited by: M Elçin, Kluwer Academic/Plenum Publishers, New York,

2003.

65. Pedrazzoli P, Ferrante P, Kulekci A, Schiavo R, Giorgi U De, Carminati O,

Marangolo M, Demirer T, Siena S, and Rosti G, on behalf of the European Group For

Blood and marrow Transplantation (EBMT), Solid Tumors Working party. Autologous

hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation

of data from the European Group for Blood and marrow Transplantation (EBMT)

Registry 1990-1999. BONE MARROW TRANSPLANTATION, Vol:32, 489-494, 2003.

66. Kröger N, Damon L, Zander A R, Wandt H, Derigs G, Ferrante P, Demirer T,

Rosti G on behalf of the EBMT Solid Tumors Working Party. Secondary acute

leukemia following mitoxantrone based high-dose chemotherapy for primary breast

cancer patients. BONE MARROW TRANSPLANTATION, 32, 1153-1157, 2003.

67. Rosti G, Demirer T, Giorgi U D, Kramar A, Droz JP, Biron P, on behalf of EBMT-

STWP and IT-94 study. Advanced Germ cell tumors: The EBMT experience and the

IT-94 study. (Book Chapter) ABMT XI-Chapter 4-Solid Tumors, 2003.

68. Demirer T. The EBMT Handbook. Haemopoietic Stem Cell Transplantation.

European School of Haematology. Editors: J Apperley, A Gratwohl. Chapter 16.4 :

Solid Tumors, Page: 277, 2004.

69. Gratwohl A, Baldomero H, Demirer T, Rosti G, Dini G, Ladenstein R, Urbano-

Ispizua A. Hematopoetic Stem cell transplantation for solid tumors in Europe.

ANNALS OF ONCOLOGY, Apr; 15 (4): 653-60, 2004.

35

35

70. Demirer T, Ayli M, Fen T, Ozcan M, Arat M, Büyükberber S, Arslan Ö, Gürman,

Akan H, Ilhan O. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by

autologous peripheral blood stem cell transplantation in patients with lmphoma: A

retrospective evaluation. BONE MARROW TRANSPLANTATION, 34, 781-786, 2004.

71. Demirer T. Autologous stem cell transplantation and allogeneic non-

myeloablative transplants in solid tumors. International Journal of Hematology-

Oncology & Bone Marrow Transplantation, Vol:1, No:3, pp: 4-8, 2004.

72. Giorgi U D, Wandt H, Lioure B, Leyvraz S, Papiani G, Ballardini M, Kulekci A,

Demirer T. First-line high-dose chemotherapy for patients with poor prognosis

extragonadal germ cell tumors. The experience of the European Bone Marrow

Transplantation (EBMT) Solid Tumors Working party. BONE MARROW

TRANSPLANTATION, Dec;34 (12): 1033-1037, 2004.

73. Giorgi U De, Demirer T, Wandt H, Taverna C, Siegert W, Bornhauser M, Kozak

T, Papiani G, Ballardini M, Rosti G. Second-line high-dose chemotherapy in patients

with mediastinal and retroperitoneal primary nonseminomatous germ cell tumors: the

EBMT experience. ANNALS OF ONCOLOGY, vol: 16 , pp: 146-151, 2005.

74. Bengala C, Guarneri V, Ledermann J, Rosti G, Wandt H, Lotz JP, Cure JH,

Orlandini C, Ferrante P, Conte PF, Demirer T on behalf of EBMT Solid Tumor Working

Party. High-dose chemotherapy with autologous hemopoietic support for advanced

ovarian cancer in first complete remission: retrospective analysis from the Solid Tumor

Registry of the European Group for Blood and marrow Transplantation (EBMT). BONE

MARROW TRANSPLANT, vol 36, pp 25-31, 2005.

36

36

75. U De Giorgi, G Rosti, S Slavin, I Yaniv, J L Harousseau, R Ladenstein, T

Demirer & G Dini on behalf of the European Group for Blood & Marrow Transplantation

Solid Tumours & Paediatric Disease Working Parties. Salvage high-dose

chemotherapy for children with extragonadal germ-cell tumours. BRITISH JOURNAL

of CANCER, Volume 93, Number 4, 412-417, 2005.

76. Peccatori J, Barkholt L, Demirer T, Sormani M.P, Bruzzi P, Ciceri F, Zambelli

A, Da Prada GA, Pedrazzoli P, Siena S, Massenkeil G, Martino R, Lenhoff S,

Corradini P, Rosti G, Ringden O, Bregni M and Niederwieser D, on behalf of EBMT

Solid Tumor Working Party. Prognostic factors for survival in patients with advanced

renal cell cancer undergoing non-myeloablative allogeneic stem cell transplantation.

CANCER JOURNAL, Vol: 104, issue 10, pages, 2099-2103, 2005..

77.Ljungman P, Urbano-Ispizua A, Cavazzini-Calvo M, Demirer T, Dini G, Einsele H,

Gratwohl A, Madrigal A, Niederwieser D, Passweg J, Rocha V, Saccardi R, Schouten

H, Socie G, Sureda A, and Apperley J for the European Group for Blood and Marrow

Transplantation. Allogeneic and autologous transplantation for haematological

diseases, solid tumours and immune disorders: definitions and current practice in

Europe. BONE MARROW TRANSPLANT, 37 (5), 439-49, 2006.

78. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkiel G,

Pedrazzoli P, Zambelli A, Bay J. O, Francois S, Martino R, Bengala C, Brune M,

Lenhoff S, Porcellini A, Falda M, Siena S, Demirer T, Niederwieser D and Ringdén

O. On behalf of the EBMT Solid Tumour Working Party. European experience of

allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma.

ANNALS OF ONCOLOGY, Vol: 17, pp1134-1140, 2006.

37

37

79. Pedrazzoli P, Ledermann JA, Lotz JP, Leyvraz S, Aglietta M, Rosti G, Champion

K, Secondino S, Selle F, Ketterer N, Grignani G, Siena S, Demirer T, on behalf of the

EBMT Solid Tumors Working Party. High-dose chemotherapy with autologous

hematopoietic stem cell support for solid tumors other than breast cancer in adults.

ANNALS OF ONCOLOGY, Vol: 17 (10), pp 1479-1488, 2006

80. Bay JO, Linassier C, Biron P, Durando X, Verrelle P, Rosti G, Demirer T, for the

EBMT Solid Tumors Working Party. Does high-dose BCNU increase overall survival in

supratentorial high-grade malignant gliomas? An EBMT retrospective study.

INTERNATIONAL JOURNAL OF CANCER, Vol:120, issue 8, pp 1782-86, 2007

81. Secondino S, Carrabba MG, Pedrazzoli P, Castagna L, Spina F, Grosso F,

Bertuzzi A, Bay JO, Siena S, Corradini P, Niederwieser D, Demirer T. Reducued

intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a

retrospective analysis of the European Group for Blood and Marrow Transplantation.

HAEMATOLOGICA, Vol:92, pp 418-20, 2007.

82. Pedrazzoli P, Rosti G, Secondino S, Carminati O, Demirer T, on behalf of

the European Group for Blood and Marrow Trasplantation (EBMT), Solid Tumors

Working Party and Gruppo Italiano di Trapianto Midollo Osseo (GITMO). High dose

chemotherapy with autologous hematopoietic stem cell support for solid tumors in

adults. SEMINARS IN HEMATOLOGY, Vol:44, pp 286-295, 2007.

83. Giorgi UD, Blaise D, Lange A, Viens P, Marangolo M, Madroszyk A, Brune M,

Afanassiev BV, Rosti G, and Demirer T. High-dose chemotherapy with peripheral

blood progenitor cell support for patients with non-small cell lung cancer: the experience

of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours

Working Party. BONE MARROW TRANSPLANTATION, Vol: 40, pp 1045-1048, 2007.

38

38

84. Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM, Bay JO,

Arpacı F, Rosti G, Gurman G, Niederwieser D, Bregni M, on behalf of the EBMT Solid

Tumors Working Party. Transplantation of allogeneic hematopoietic stem cells: an

emerging treatment modality for solid tumors. NATURE CLINICAL PRACTICE

ONCOLOGY, Vol: 5, No: 5, pp 256-267, 2008.

85. İlhan O, Topçuoğlu P, Arat M, Soydan EA, Yuksel MK, Arslan Ö, Özcan M,

Gürman G, Demirer T, Akan H, Konuk N, Uysal A. Allogeneic hematopoietic stem cell

transplantation (allo-HSCT) in acute myeloblastic leukemia (AML): A single center

experience, TURK J HAEMATOL Pages 87 – 93, Vol:25, ıssue 2, 2008.

86. Ueno N T, Rizzo D, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M,

Rondon G, Champlin RE, Antman K, Stiff PJ, Horowitz MM, Niederwieser D.

Allogeneic hematopoietic cell transplantation for metastatic breast cancer. BONE

MARROW TRANSPLANT, Vol: 41, pp 537-545, 2008.

87. Ladenstein R, Pötschger U, Hartman O, Pearson ADJ, Klingebiel, Castel V,

Yaniv I, Demirer T, and Dini G, on behalf of the EBMT Paediatric Working Party. 28

years of hıgh-dose therapy and SCT for neuroblastoma in Europe: lessons from more

than 4000 procedures. BONE MARROW TRANSPLANTATION, Vol: 41, S 118-127,

2008.

88. Aglietta M, Barkholt L, Carnevale Schianca F Caravelli D, Omazic B, Minotto C,

Leone F, Hentschke P. Bertoldero G , Capaldi A, Ciccone G, Niederwieser D,

Ringdén O, Demirer T, On behalf of the EBMT Solid Tumor Working Party. Reduced

Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal

Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood

and Marrow Transplantation Experience. BIOLOGY of BLOOD and MARROW

TRANSPLANTATION, vol: 15, ıssue 3, pages: 326-335, 2009..

39

39

89. Aktaş B, Topcuoglu P, Kurt ÖK, Ensari A, Demirer T. Severe Henoch-Schönlein

Purpura induced by Cytarabine. THE ANNALS OF PHARMACOTHERAPY, Letter, vol:

43 (4), pp 792-3, 2009.

90. Ozcelik T, Topcuoglu P, Beksac M, Ozcan M, Arat M, Bıyıklı Z, Bakanay SM,

Ilhan O, Gurman G, Arslan O, Demirer T. Mobilization of PBSCs with chemotherapy

and recombinant human G-CSF: a randomized evaluation of early vs late administration

of recombinant human G-CSF. BONE MARROW TRANSPLANTATION, Vol: 44, No:

12, pp 779-783, 2009.

91. Bay JO, Cabrespine-Faugeras A, Tabrizi R, Blaise D, Viens P, Ehninger G,

Bornhauser M, Slavin S, Rosti G, Demirer T, Bregni M. Allogeneic stem cell

transplantation in ovarian cancer. The EBMT Experience. In Press, INT. J. CANCER.

92. DA Berry, NT Ueno, MM Johnson, X Lei, J Caputo, S Rodenhuis, WP Peters, RC

Leonard, SI Bearman, MS Tallman, J Bergh, UA Nitz, A Gianni, RL Basser, AR Zander,

RC Coombes, H Roche, Y Tokuda, JG Schrama, GN Hortobagyi, M Bregni, T.

Demirer. High dose chemotherapy with autologous stem cell support versus standard-

dose chemotherapy: Overview of individual patient data from 15 randomized adjuvant

therapy breast cancer trials. J. CLIN. ONCOL, 29 (24), pages: 3214-3223, 2011

93. DA Berry, NT Ueno, MM Johnson, X Lei, J Caputo, D Smith, L Yancey, M Crump,

EA Stadmauer, H Roche, JP Crown, P Schmid, JP Lotz, M Bregni, T. Demirer. High

dose chemotherapy with autologous hematopoietic stem cell transplantation versus

standard-dose chemotherapy: Overview of individual patient data from six randomized

metastatic breast cancer trials. J. CLIN. ONCOL, 29 (24), pages: 3224-31, 2011

40

40

94. P Pedrazzoli, P Comoli, D Montagna, T Demirer, M Bregni on behalf of the

EBMT Solid Tumors Working Party. Is adoptive T-Cell Therapy for solid tumors coming

of age? BONE MARROW TRANSPLANTATION, Vol: 47 (8), Pages: 1013-1019,

2012.

95. SM Bakanay, T Demirer. Novel agents and approaches fors tem cell

mobilization in normal donors and patients. BONE MARROW TRANSPLANTATION,

47, pages: 1154-1163, 2012.

96. Stem Cell Transplantation- An Introduction. T Demirer, Editor. Stem Cell

Transplantation. Edited by: T. Demirer, Published by Intech, 2012.

97. P Pedrazzoli, G Rosti, S Secondino, M Bregni, T Demirer, on

behalf of the European Group for Blood and Marrow Trasplantation (EBMT), Solid

Tumors Working Party. Intensified chemotherapy with stem cell support for solid

tumor in adults: 30 years of investigations can provide some clear answers?

Chapter 18, pages 371-380, Book Chapter In Stem Cell Transplantation, Edited

by: T. Demirer, Published by Intech, 2012

98. Y Koç, T Demirer. Mantle Cell Lymphoma : Decision making for transplant.

? Chapter 15, pages 319-344, Book Chapter In Stem Cell Transplantation,

Edited by T. Demirer, Published by Intech, 2012.

99. Ş.M. Bakanay, T Demirer. Stem Cell Mobilization In Multiple Myeloma. ?

Chapter 13, pages241-262, Book Chapter In Multiple Myeloma- An Overwiew,

Edited by Ajay Gupta, Published by Intech, 2012

41

41

100. T. Demirer. Response to ‘Are there still reasons to believe that high-dose

chemotherapy have a role in breast cancer management ? Letter to Editor, BONE

MARROW TRANSPLANTATION, Vol: 48, issue: 2, pp 305-6, 2013.

101. C. Soydal, E. Ozkan, M. Araz, Ö Kucuk, T. Demirer. Intense Ga-68 Dotatate

uptake in recurrent MTC patient. World Journal of Endocrine Surgery, Vol: 4(3), pp

118-119, 2012.

102. Innovations in Stem Cell Transplantation- An Introduction. T Demirer,

Editor. Innovations in Stem Cell Transplantation. Edited by: T. Demirer, Published

by Intech, pp VII-VIII, 2013.

103. L Kaynar, M. Çetin, A Ünal, T Demirer. Current Status of Hematopoietic

Stem Cell Transplatation in Patients with Refractory or Relapse Hodgkin

Lymphoma. Chapter 13, pages 289-304, Book Chapter In Innovations inStem Cell

Transplantation, Edited by T. Demirer, Published by Intech, 2013.

104. Z A Yegin, G T Sucak, T Demirer. Iron Overload and Hematopoietic Stem

Cell Transplantation. Chapter 14, pages305-329, Book Chapter In Innovations

inStem Cell Transplantation, Edited by T. Demirer, Published by Intech, 2013.

105. P. Topcuoglu, S.C. Bozdag, T Demirer. Allogeneic Hematopoietic Stem

Cell Transplantation in Multiple Myeloma. Chapter 8, pages165-177, Book

Chapter In Multiple Myeloma- A Quick reflection on the fast progress. Edited by R.

Hajek, Published by Intech, 2013.

42

42

106. P Pedrazzoli, M Bregni, G Rosti, F Lanza, T Demirer. Autologous Stem Cell

Transplantation : Is it still relevant in breast cancer. Breast Cancer Management, Vol :

2(6), pp : 447-450, 2013.

107. C. Soydal, E. Ozkan, M. Araz, Ö Kucuk, T. Demirer. Recurrent medullary

carcinoma detected by Gallium-68 positron emission tomography. World Journal of

Endocrine Surgery, Vol: 5(2), pp 59-60, 2013.

108. M. Martino, F. Lanza, M. Mohty, T. Demirer, T. Martinello, S. Secondino, P.

Pedrazzoli on behalf of the European Society for Blood and Marrow Transplantation,

Solid Tumors Working party (EBMT-STWP). Erythropoiesis-stimulating agents in

allogeneic and autologous hematopoietic stem cell transplantation. Expert Opin Biol

Ther, 15 (2): 195-211, 2015.

109. M Özen, S Bozdağ, G Çakmak, P Topçuoğlu, Ö Arslan, T Demirer, H Akan, O

İlhan, G Gürman, M Özcan. Antilymphocyte/thymocyte globulin for the treatment of

steroid-refractory acute graft-versus-host disease: 20-year experience at a single

center. International Journal of Hematology/Oncology, Pp 236-244, No: 4, Vol: 25,

2015

110. P Topcuoglu, SC Bozdag, T Demirer. Use of Monoclonal Antibodies in

Conditioning Regimenin Transplantation. Chapter 3, pp 43-56, Book Chapter, in

Progress in Stem Cell Transplantation. Edited by, T. Demirer, Published by Intech,

2015.

43

43

2016 (Yayın Yılı)

111. Mehmet Özen, Gülden Yılmaz, Belgin Coşkun, Pervin Topçuoğlu, Önder Arslan,

Muhit Özcan, Taner Demirer, Osman İlhan, Nahide Konuk, İsmail Balık, Günhan

Gürman, Hamdi Akan . A quasi-experimental study analyzing the effectiveness of

portable HEPA filters in preventing infections in hematology patients during

construction. Turkish Journal of Hematology, Vol: 33, pp 41-47, 2016

112. Demirer T. Autologous Stem Cell transplantation in breast Cancer: Is There Still

a Hope?. International Journal of Hematology/Oncology, No: 3, Vol: 26, pp 182-

187, 2016.

113. Sahin U, Toprak SK, Atilla Ataca P, Atilla E, Demirer T. An Overview of

Infectious Complications after Allogeneic Hematopoietic Stem Cell Transplantation.

Journal of Infection and Chemotherapy, Vol: 22, pp 505-514, 2016.

114. Şahin U, Atilla-Ataca P, Atilla E, Koçak ST, Demirer T. An Overview of

Hematopoietic Stem Cell Transplantation Related Thrombotic Complications. Critical

Reviews in Oncology/Hematology, Vol: 107, pp 149-155, 2016.

115. Karadurmuş N, Arpacı F, Şahin U, Demirer T. A Review of Allogeneic

Hematopoietic Stem Cell Transplantation With Reducued Intensity Conditioning in Solid

Tumors Other Than Breast Cancer. World Journal of Transplantation, Vol: 6(4), pp

675-681, 2016.

116) Ataca P, Atilla E, Toprak SK, Demirer T. Non-Infectious Early Complications of

Allogeneic Stem Cell Transplantations. International Journal of

Hematology/Oncology, Vol: 26, No: 4, pp 239-250, 2016.

44

44

2017 (Yayın Yılı)

117. Atilla E, Atilla Ataca P, Demirer T. A Review of Myeloablative vs Reduced

Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell

Transplantations. Balkan Med J, Vol: 34, No: 1, pp 1-9, 2017.

118. Atilla E, Toprak S. Koçak, Demirer T. Current Review of Iron Overload and

Related Complications In Hematopoietic Stem Cell Transplantation. Turkish Journal of

Hematology, Vol: 34, pp 1-9, 2017.

119. M Ö zen, C Ustun, P Topcuoglu, M Arat, M Gundu z, E Atilla, O Arslan, T

Demirer, H Akan, O lhan, M Beksac , N Konuk, G Gurman. Comparison of Allogeneic

Stem Cell Transplantation in Chronic Myeloid Leukemia And the Effect of Thyrosine

kinase inhibitors on survival. A Quasi-experimental study. Turkish Journal of

Hematology, 34 (1), pp 1-9, 2017.

120. Atilla E, Atilla Ataca P, Demirer T. Current Treatment Strategies in

Relapsed/Refractory Mantle Cell Lymphoma: Where are we now? International

Journal of Hematology, Vol:105, pp 257-264, 2017.

121. Karadurmuş N, Şahin U, Arpacı F, Demirer T. An Overview of High Dose

Chemotherapy With Autologous Stem Cell Rescue For Germ Cell Tumors In Current

Practice. Balkan Union of Oncology, Vol: 22 (2), pp 306-311, 2017 .

122. Atilla Ataca P, Ozturk Sule Mine, Demirer T. How to manage poor mobilizers for

High Dose Chemotherapy and Autologous Stem Cell Transplantation ?. Transfusion

and Apheresis Science, Vol: 56, ıssue:2, pp 190-198, 2017.

45

45

123. Atilla E, Atilla Ataca P, Toprak SK, Demirer T. A Review of Late Complications

of Allogeneic Hematopoietic Stem Cell Transplantations. Clinical Transplantation,

Vol: 31, No: 10, pp: , 2017.

124. Atilla Ataca P, Atilla E, Bozdağ SC, Demirer T. A Review of Infectious

Complications After Haploidentical Hematopoietic Stem Cell Transplantations.

Infection, 45:403-411, 2017.

125. Gündüz M, Sahin U, Toprak SK, Bozdag SC, Yuksel MK, Arslan O, Özcan M,

Demirer T, Beksac M, Ilhan O, Gurman G, Topcuoglu P. Subsequent Malignancies

After Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Transplantation,

Vol: 31, No: 7, 2017.

126. Atilla E, Civriz Bozdag S, Kurt M, Toprak S, Topcuoglu P, Demirer T, Ilhan O,

Arslan O, Gurma G, Ozcan M. Treatment with methotrexate, rituximab and cytosine-

arabinoside followed by autologous stem cell transplantation in primary CNS

lymphoma: A single center experience. Accepted in Hematology/Oncology and Stem

Cell Therapy.

127. Demirer T. Preface. In Haploidentical Stem Cell Transplantation: An Emerging

Treatment Modality. Edited by Taner DEMİRER. Published by Humana Press, Springer

International Publishing, 2017.

128. Yüksel M K, Demirer T. Toxicity of Conditioning Regimens in Haploidentical

Stem Cell Transplantation. In Haploidentical Stem Cell Transplantation: An Emerging

Treatment Modality. Edited by Taner DEMİRER. Published by Humana Press, Springer

International Publishing, Chapter 4, pages 43-56, 2017.

46

46

129. Sahin U, Demirer T. Future Perspectives for Haploidentical Stem Cell

Transplantation. In Haploidentical Stem Cell Transplantation: An Emerging Treatment

Modality. Edited by Taner DEMİRER. Published by Humana Press, Springer

International Publishing, Chapter 13, pages 189-199, 2017.

130. Atilla E, Atilla PA, Bozdag SC, Yuksel MK, Toprak SK, Topcuoglu P, Akay BN,

Sanli H , Akan H, Demirer T, et al. Extracorporeal photochemotherapy in mycosis

fungoides. TRANSFUSION CLINIQUE ET BIOLOGIQUE, Volume: 24,Issue: 4,Pages:

454-457, 2017.

2018 Yayın Yılı

131. Karadurmus N, Basgöz BB, Sahin U, Demirer T. Is there a role of high dose

chemotherapy and autologous stem cell transplantation in the treatment of Ewing's

sarcoma and osteosarcomas? Balkan Union of Oncology, Vol: 23, No: 5, pp 1235-

1241, 2018.

132. Seval Cengiz G, Topcuoglu P, Demirer T. Current Approach to Non-Infectious

Pulmonary Complications of Hematopoietic Stem Cell Transplantation. Balkan Med J,

Vol: 35, No: 2, pp 131-40, 2018.

133. Karadurmus N, Sahin U, Arpaci F, Demirer T. A review of allogeneic

hematopoietic stem cell transplantation in patients with metastatic breast cancer. Int. J

of Hemat/Oncology and Stem Cell Research, Vol : 12, No : 2, pp 111-116, 2018.

47

47

134. Sahin U, Demirer T. Current strategies for the management of autologous

peripheral blood stem cell mobilization failures in patients with multiple myeloma.

Journal of Clinical Apheresis, Vol : 33, No :3, pages 357-370, 2018.

135. Bozdağ SC, Kurt MY, Demirer T. Adult Stem Cells. Advances in Experimental

Medicine and Biology, vol : 1079, pp 17-36, 2018.

136. Uckun FM, Qazi S, Demirer T, Champlin RE. Contemporary Patient-Tailored

Treatment Strategies Against High Risk and Relapsed or Refractory Multiple Myeloma.

In Press, EBioMedicine.

137. Atilla E, Atilla Ataca P, Seval GC, Bektaş M, Demirer T. Current approach to

early gastrointestinal and liver complications of hematopoietic stem cell transplantation.

In Press, Turk J Gastroenterol.

BOOKS

1. EBMT Solid Tumors Working Party and Registry. 2001 Activity Report. Edited

by: Demirer T and Kulekci A.N. Ankara University Press, Total pages: 166, February

2002.

2. EBMT Solid Tumors Working Party and Registry. 2002 Activity Report. Edited

by: Demirer T and Kulekci A.N. Ankara University Press, Total pages: 160, January

2003.

48

48

3. EBMT Solid Tumors Working Party and Registry. 2003 Activity Report. Edited

by: Demirer T and Kulekci A.N. Ankara University Press, Total pages: 52, February

2004.

EDITORSHIP 1. Stem Cell Transplantation. Edited by: Taner Demirer. Published by InTech

Company, total pages 582, 2012.

2. Innovations in Stem Cell Transplantation. Edited by: Taner Demirer.Published

by InTech Company, total pages 370, 2013.

3. A Report of National Stem Cell Policies in Turkey. Published by The Turkish

Academy of Sciences. Edited by: Alp Can and Taner Demirer, total pages 53,

2014.

4. A Report of National Cancer Policies in Turkey. Published by The Turkish

Academy of Sciences. Edited by: Taner Demirer, Nur Olgun and Ahmet Özet,

total pages 93, 2014.

5. A Report of problems experienced in related to coordination during treatment of

cancer patients in Turkey. Published by The Turkish Academy of Sciences.

Edited by: Taner Demirer, total pages 93, 2014.

6. A report of Nutrition and Cancer. Published by The Turkish Academy of

49

49

Sciences. Edited by: Taner Demirer, total pages 155, 2015.

7. Progress in Stem Cell Transplantation. Edited by: Taner Demirer. Published by

InTech Company, total pages 197, 2015.

8. Haploidentical Stem Cell Transplantation: An Emerging Treatment Modality.

Edited by Taner DEMİRER. Published by Humana Press, Springer International

Publishing, total pages 200, 2017.

9. TÜBA A report of phase studies in Clinical research . Edited by: Taner

DEMİRER, Total pages: 120 , January 2017.

10. TÜBA Food Safety Symposium Edited by: Taner DEMİRER, total pages 148,

October 2017.

50

50

ABSTRACTS

1. Kucuk O, Demirer T, Gilman-Sachs A, Westerman M.P. et al: Correlation of

DNA ploidy with stage and histology in prostate cancer patients. Proceedings of the

American Association for Cancer Research, Volume 32, Abs. No:160, March 1991.

2. Demirer T, Buckner C.D, Petersen F.B, Appelbaum F, Rowley S, Lilleby K,

Sanders J, Chauncey T, Storb R, Benyunes MC, Fefer A, and Bensinger W.: Rapid

engraftment after autologous transplantation utilizing marrow and recombinant

granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells in

patients with acute myelogenous leukemia (AML). "BLOOD" Vol:84, No:10, Suppl 1,

pp 92a, Abstr:356, 1994.

3. Demirer T, Gooley T, Buckner CD, Petersen FB, Lilleby K, Rowley S, Sanders J,

Storb R, Appelbaum FR, Bensinger WI: The influence of total nucleated cell dose from

marrow harvests on outcome in patients with acute myelogenous leukemia undergoing

autologous transplantation. "BLOOD" Vol:84, No:10, Suppl 1, pp 348a, Abstr:1376,

1994.

4. Demirer T, Bensinger WI, Rowley S, Appelbaum FR, Petersen FB, Chauncey T,

51

51

Fefer A, Buckner CD: Comparison of granulocyte-colony stimulating factor mobilized

peripheral blood stem cells and bone marrow for autologous transplantation in patients

with acute myelogenous leukemia. "BLOOD" Vol:86, No:10, Suppl 1, pp 99a,

Abstr:381, 1995.

5. Demirer T, Bensinger WI, Appelbaum FR, Rowley S, Buckner CD: Autologous

stem cell transplantation for patients with multiple myeloma. "BLOOD" Vol:86, No:10,

Suppl 1, pp 207a, Abstr:815, 1995.

6. Chauncey TR, Gooley TA, Appelbaum FR, Demirer T, Holmberg L, Lilleby K,

Rowley SD, Buckner CD: Quantitative CD34 collection does not independently predict

clinical outcome after autologous PBSC transplantation. "BLOOD" Vol:86, No: 10,

Suppl 1, pp 941a, Abstr: 3751, 1995.

7. Demirer T, Buckner CD, Storer B, Rowley S, Schiffman K, Bensinger WI: The

effect of different chemotherapy regimens on peripheral blood stem cell mobilization

yield. ASCO proceedings. Vol:15, P:345, Abstr:1007, 1996.

8. Holmberg L.A, Demirer T, Schiffman K, Rowley SD, Buckner CD, Goodman G,

Maziarz R, Appelbaum FR, and Bensinger WI: High-dose busulfan, melphalan, and

thiotepa (BUMELTT) followed by autologous peripheral blood stem cells (PBSC) rescue

in patients with advanced stage III/IV ovarian cancer. “BLOOD” , Vol:90, No:10, Suppl

1(part 1 of 2) abstr:1705, 1997.

9. Arat M, Üstün C, Arslan Ö, Ayyıldız E, Koç H, Beksaç M, Akan H, Gürman G,

Özcan M, Demirer T, Uysal A, Konuk N, İlhan O: Correlation of CD34+ mononuclear

cells and engraftment time in allogeneic peripheral blood stem cell transplantation.

Boletim da Sociedade Brasileira de Hematologia a hemoterapia (VII International

Congress of the World Apheresis Association-WAA), Abstract C 75, pp 176, Volume

52

52

XX-Suplemento Outubro 1998, ISSN 0102-7662.

10. M. Özcan, C. Üstün, O. İlhan, M. Beksaç, E. Akçağlayan, G. Gürman, H. Akan,

T. Demirer, M. Arat, H. Çelebi, N. Konuk, A. Uysal. The effect of G-CSF in the first 100

days of allogeneic peripheral blood stem cell transplantation. BLOOD Vol:92, No:10,

Suppl 1 (part 2 of 2), abstr:4405, pp 326b, 1998.

11. G. Gürman, C. Üstün, Ö. Arslan, M. Beksaç, N. Konuk, M. Arat, H. Çelebi, M.

Özcan, O İlhan, T. Demirer, H. Akan, A. Uysal, H. Koç. Allogeneic hematopoietic

stem cell transplantation in patients with advanced hematological malignancies by using

non-myeloablative conditioning regimen. BLOOD Vol:92, No:10, Suppl 1 (part 2 of 2),

abstr:4509, pp 350b, 1998.

12. C. Üstün, M. Özcan, M. Beksaç, O İlhan, M. Çakır, G. Gürman, H. Akan, T.

Demirer, M. Arat, H. Çelebi, N. Konuk, A. Uysal. Clinical effects of intravenous immüne

globulin (IVIG) treatment in patients with allogeneic peripheral stem cell transplantation.

BLOOD Vol:92, No:10, Suppl 1 (part 2 of 2), abstr:4528, pp 355b, 1998.

13. Üstün C, İdilman R, Özcan M, Akan H, Karayalçın S, Gürman G, İlhan O, Beksaç

M, Uysal A, Konuk N, Demirer T, Koç H. Which hematopoietic stem cell

transplantation type is safe for patients with hepatitis B virus carriers. HEPATOLOGY

vol: 28, No 4, S, pp 2221, 1998.

14. Gürman G, Üstün C, Arslan Ö, Beksaç M, Konuk N, Arat M, Çelebi H, Özcan M,

İlhan O, Demirer T, Akan H, Uysal A, Koç H: Allogeneic hematopoietic cell

transplantation in patients with advanced hematological malignancies by using non-

myeloablative conditioning regimen. BONE MARROW TRANSPLANTATION, Vol:23,

53

53

Suppl 1, abstr:70, S22, 1999.

15. Üstün C, Özcan M, Beksaç M, İlhan O, Çakır M, Gürman G, Arslan Ö, Akan H,

Demirer T, Arat M, Çelebi H, Konuk N, Uysal A, Koç H: Clinical effects of intravenous

immune gloguline (IVIG) treatment in patients with allogeneic peripheral stem cell

transplantation. BONE MARROW TRANSPLANTATION, Vol:23, Suppl 1, abstr:567,

S171, 1999.

16. Demirer T, Arat M, Koç H, İlhan O, Çelebi H, Özcan M, Akan H, Gürman G,

Uysal A: A protocol proposal comparing conventional approach with high-dose

chemotherapy (HDC) and peripheral blood stem cell transplantation (PBSCT) in

patients with small cell lung cancer limited to thorax. BONE MARROW

TRANSPLANTATION, Vol:23, Suppl 1, abstr:625, S189, 1999.

17. Demirer T, Arat M, Koç H, İlhan O, Akan H, Gürman G, Özcan M, Çelebi H,

Üstün C, Uysal A: A protocol proposal for high-dose chemotherapy (HDC) with

autologous peripheral blood stem cell transplantation (PBSCT) versus conventional

chemotherapy in patients with relapsed cisplatin sensitive epithelial ovarian cancer-2

arm randomized study. BONE MARROW TRANSPLANTATION, Vol:23, Suppl 1,

abstr:626, S189, 1999

18. Ilhan O, Demirer T, Arat M, Dalva K, Coşkun Ş, Beksaç M, Akan H, Özcan M,

Arslan Ö, Gürman G, Koç H: The influence of CD41+ and CD42+ peripheral blood stem

cells on platelet engraftment after allo PBSCT. BONE MARROW

TRANSPLANTATION, Vol:23, Suppl 1, abstr:672, S201, 1999

19. Özcan M, Üstün C, İlhan O, Beksaç M, Akçağlayan E, Gürman G, Akan H,

Demirer T, Arat M, Çelebi H, Konuk N, Uysal A, Koç H: The effect of G-CSF in the first

54

54

100 days of allogeneic peripheral blood stem cell transplantation. BONE MARROW

TRANSPLANTATION, Vol:23, Suppl 1, abstr:688, S205, 1999

20. Arat M, Demirer T, Ilhan O, koç H, Üstün C, Çelebi H, Ayyıldız E, Tüzün A,

Gürman G, Özcan M: Peripheral blood stem cell (PBSC) collection with

cyclophosphamide (CY) – paclitaxel and recombinant human granulocyte-colony

stimulating factor (rhG-CSF) in patients with breast cancer: Ibn-i Sina experience.

BONE MARROW TRANSPLANTATION, Vol:23, Suppl 1, abstr:713, S212, 1999

21. Arat M, Demirer T, Üstün C, Çelebi H, Tüzün A, Coşkun Ş, Ayyıldız E, İlhan O,

Gürman G, Özcan M, Koç H. A phase I dose escalation study of high dose thiotepa,

melphalan and carboplatin in patients with high risk breast cancer and hematologic

malignancies. Proceedings of ASCO Vol:18, abstract 207, pp 56a, 1999.

22. Beksaç M, Akan H, Koç H, İlhan O, Uysal A, Özcan M, Demirer T, Konuk N et

al: Comparison of allogeneic peripheral blood stem cell transplantation: A prospective

randomized EBMT study. Results of Ankara University. Turk J Haematol, 16, 3 (suppl

1): abstr 40, pp 138, 1999.

23. Özcan M, Üstün C, İlhan O, Beksaç M, Akçağlayan E, Arslan Ö, Gürman G,

Akan H, Demirer T, et al: The effect of G-CSF in the first 100 days of allogeneic

peripheral blood stem cell transplantation. Turk J Haematol, 16, 3 (suppl 1): abstr 43,

pp 140, 1999.

24. Demirer T, İlhan O, Mandel NM, Arat M, Çelebi HA phase I dose escalation

study of high-dose thiotepa, melphalan, and carboplatin (TMCb) followed by autologous

peripheral blood stem cell (PBSC) transplantation in patients with solid tumors and

hematologic malignancies. Turk J Haematol, 16, 3 (suppl 1): abstr 44, pp 140, 1999.

25. Arslan Ö, Coşkun HŞ, Üstün C, Arat M, Çelebi H, Özcan M, Gürman G, Akan H,

55

55

İlhan O, Konuk N, Demirer T, et al: Experience of ibn-I sina hospital in allogeneic

peripheral blood stem cell transplantation for standard risk leukemia patients. Turk J

Haematol, 16, 3 (suppl 1): abstr 46, pp 141, 1999

26. Üstün C, Özcan M, Beksaç M, İlhan O, Çakır M, Gürman G, Arslan Ö, Akan H,

Demirer T, et al: Clinical effects of intravenous immune globuline (IVIG) treatment in

patients with allogeneic peripheral blood stem cell transplantation. Turk J Haematol,

16, 3 (suppl 1): abstr 49, pp 143, 1999

27. Gürman G, Üstün C, Arslan Ö, Beksaç M, konuk N, Arat M, Çelebi H, Özcan M,

İlhan O, Demirer T et al: Allogeneic hematopoietic cell transplantation in patients with

advanced hematological malignancies by using nonmyeloablative conditioning regimen.

Turk J Haematol, 16, 3 (suppl 1): abstr 50, pp 143, 1999

28. Ilhan O, Demirer T, Arat M, Dalva K, Coşkun HŞ, et al: The influence of CD41+

and CD42+ peripheral blood stem cells on platelet engraftment after allo PBSCT.

Turk J Haematol, 16, 3 (suppl 1): abstr 51, pp 144, 1999

29. Arslan Ö, Arat M, İlhan O, Ayyıldız E, Üstün C, Çelebi H, Tekin M, Özcan M,

Gürman G, Demirer T et al: The influence of donors peripheral blood CD34+ cells on

collection and engraftment kinetics in allogeneic peripheral blood stem cell

transplantation. Turk J Haematol, 16, 3 (suppl 1): abstr 52, pp 144, 1999

30. Arslan Ö, Coşkun HŞ, Akçağlayan E, Özcan M, Gürman G, Arat M, Çelebi H,

Demirer T, et al: Comparison of ABO/Rh blood group incompatible and compatible

patients in allogeneic peripheral blood stem cell transplantation. Turk J Haematol, 16,

3 (suppl 1): abstr 53, pp 145, 1999

31. Arslan Ö, Arat M, Üstün C, Çelebi H, Özcan M, Gürman G, Tekin M, Ayyıldız E,

Demirer T et al: The influence ofdonors peripheral blood CD34+ cells on collection and

56

56

engraftment kinetics in allogeneic peripheral blood stem cell transplantation. Turk J

Haematol, 16, 3 (suppl 1): abstr 55, pp 146, 1999

32. Arat M, Arslan Ö, Ayyıldız E, Akan H, Koç H, Özcan M, Gürman G, Demirer T et

al: CD34 positive stem cell selection with isolex 300I: The first live procedure in Turkey.

Turk J Haematol, 16, 3 (suppl 1): abstr 56, pp 146, 1999

33. Özcan M, Çelebi H, Gürman G, Arslan Ö, Demirer T et al: Treatment of

refractory AGVHD with anti-thymocyte globulin. Turk J Haematol, 16, 3 (suppl 1): abstr

57, pp 147, 1999

34. İlhan O, Demirer T, Arat M, Arslan Ö, Dalva K, et al: Platelet engraftment after

allo PBSCT: the role of CD41+ and CD42+ stem cells. Haematologica, vol:84, EHA-4

Abstr book, abstr PO-0282, pp 66, 1999.

35. Arslan Ö, Coşkun HŞ, Üstün C, Arat M, Çelebi H, Özcan M, Gürman G, Akan H,

İlhan O, Konuk N, Demirer T et al: Experience of Ibn-I Sina Hospital in allogeneic

peripheral blood stem cell transplantation for standar risk leukemia patients.

Haematologica, vol:84, EHA-4 Abstr book, abstr PO-0283, pp 66, 1999.

36. Demirer T, Ilhan O, Arat M, Günel N, Çelebi H, Özcan M, Gürman G, Akan H,

Uysal A, Koç H. A phase I dose escalatıon study of high dose thiotepa, melphalan, and

carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation

(PBSCT) in patients with solid tumors and hematologic malignancies. Bone Marrow

Transplantation, vol 25, suppl 1, abstr P905, page S279.

37. Aylı M, Çelik Z, Oymak A, Fen T, Tekin K, Eser N, Demirer T. Mobilization of

hematopoietic progenitor cells with paclitaxel, cyclophosphamide (CY) and recombinant

57

57

human granulocyte-colony stimulating factor (rh-GCSF) in patients with lymphoid

malignancies and breast cancer. The Hematology Journal, Vol 1, suppl 1, abstr 743,

pp 190, 2000.

38. Aylı M, Fen T, Demirer A, Çelik Z, Oymak A, Özdel Ö, Demirer T. CD34+ PBSC

mobilization with cyclophosphamide (CY), paclitaxel and recombinant human

granulocyte colony stimulating factor (Rh-GCSF) in patients with lymphoid

malignancies. Annals of Oncology, Vol 11, Suppl 4, 439P, 2000.

39. Demirer T, Aylı M, Demirer A et al. Peripheral blood stem cell (PBSC)

collection with cyclophosphamide (CY), etoposide and recombinant human granulocyte-

colony stimulating factor (rhG-CSF) in patients with hematologic malignancies and solid

tumors. BLOOD, Vol: 96, No: 11 (part 1 of 2 parts), abstract: 5105, pp 314b, 2000.

40. Demirer T, Aylı M, Demirer A, et al. Peripheral blood stem cell (PBSC)

collection with cyclophosphamide (CY), epirubicin and recombinant human granulocyte-

colony stimulating factor (rhG-CSF) in patients with breast and ovarian cancer.

BLOOD, Vol: 96, No: 11 (part 1 of 2 parts), abstract: 5106, pp 315b, 2000.

41. Ilhan O, Arslan Ö, Arat M, Özcan M, Gürman G, Dalva K, Beksaç M, Demirer T

et al. The value of peripheral blood CD34+ cell quantitation in autologous

hematopoietic stem cell apheresis. BLOOD, Vol: 96, No: 11 (part 1 of 2 parts),

abstract: 5111, pp 316b, 2000.

42. Demirer T, Ilhan O, Aylı M, et al. Phase-II study of high-dose thiotepa,

melphalan, and carboplatin (TMCb) with autologous peripheral blood stem cell (PBSC)

support in patients with hematologic malignancies and solid tumors. BLOOD, Vol: 96,

No: 11 (part 1 of 2 parts), abstract: 5344, pp 368b, 2000.

43. Demirer T, Ilhan O, Aylı M, Arat M, Fen T et al. High-dose thiotepa, melphalan

58

58

and carboplatin (TMCb) with autologous peripheral blood stem cell (PBSC) support in

patients with hematologic malignancies and solid tumors. Bone Marrow

Transplantation, Vol:27, Suppl 1, EBMT 2001.

44. Demirer T, Ilhan O, Aylı M, et al. Cyclophosphamide (CY), etoposide (E) and

granulocyte-colony stimulating factor (G-CSF) for the collection of peripheral blood stem

cells. ASCO Proceedings, Abstract 67, pp 18a, Poster presentation, 2001.

45. Demirer T, Aylı M, Ilhan O, et al: Peripheral blood stem cell (PBSC) collection

with cyclophosphamide (CY), etoposide (E) and granulocyte-colony stimulating factor :

The effect of preleukapheresis circulating (PLC) CD34 cells on the yield. The

Hematology Journal, Volume-I, Suppl 1, Poster 761, 2001.

46. Demirer T, Aylı M, Günel N, et al: A randomized study of comparison of

leukapheresis volumes 8 L versus 10 L. The Hematology Journal, Volume-I, Suppl 1,

Abstract 768, 2001.

47. Arat M, Arslan Ö, Özcan M, Gürman G, Beksaç M, Koç H, Ayyıldız E, Topçuolu

P, Dalva K, Demirer T, Uysal A, Konuk N, Ilhan O. Allogeneic peripheral blood stem

cell apheresis : Ibn-i sina experience. XIII Congress of the European Society for

Haemapheresis. Rıva del Garda, Italy, page 64, 2001, Oral presentation.

48. Demirer T, Aylı M, Günel N et al. A randomized trial of assessment of efficacy

of leukapheresis volumes, 8 L versus 10 L. XIII Congress of the European Society

for Haemapheresis. Rıva del Garda, Italy, page 67, 2001, Oral presentation.

49. Arat M, Arslan Ö, Ayyıldız E, Çitçi A, Demirer T, Ilhan O. Stem cell mobilization

with cyclophosphamide (CY) based regimen in multiple myeloma: Ibn-i Sina

59

59

Experience. XIII Congress of the European Society for Haemapheresis. Rıva del

Garda, Italy, Poster, page 171, 2001.

50. Arslan Ö, Arat M, Ozcan M, Gürman G, Koç H, Ahan H, Demirer T et al.

Autologous peripheral blood stem cell mobilization: Ibn-i Sina Experience. XIII

Congress of the European Society for Haemapheresis. Rıva del Garda, Italy,

Poster, page 174, 2001.

51. Demirer T, Aylı M, Ozcan M, et al: Mobilization of peripheral blood stem cells

with chemotherapy and recombinant human granulocyte colony stimulating factor (rhG-

CSF): A randomized evaluation of different doses of Rh-GCSF. XIII Congress of the

European Society for Haemapheresis. Rıva del Garda, Italy, Poster, page 184, 2001.

52. Ilhan O, Arat M, Arslan O, Ozcan M, Gürman G, Demirer T, Konuk N, Uysal A,

Akan H: Evaluation of Mobilization efficiency of cyclophosphamide (CY) based regimen

by peripheral blood CD34+ cell quantification. XIII Congress of the European Society

for Haemapheresis. Rıva del Garda, Italy, Poster, page 192, 2001.

53. Bengala C, Guarneri V, Ledermann J, Wandt H, Lotz J, Cure J, Rosti G,

Ferrante P, Demirer T, Conte P on behalf of the Solid Tumour Working Party of the

EBMT. High-dose chemotherapy with autologous hemopoietic support for advanced

ovarian cancer in 1st complete remission: retrospective analysis from Solid Tumor

Registry of the European Group for Blood and Marrow Transplantation. Bone Marrow

Transplantation, Vol 29, Suppl 2, S 32, abstr 200 , 2002, (Oral Presentation).

54. Demirer T. The EBMT Solid Tumours Working Party (STWP) Registry: 2001

report. Bone Marrow Transplantation, Vol 29, Suppl 2, S 189, abstr 702 (Poster

presentation), 2002.

60

60

55. Demirer T, Aylı M, Ozcan M,et al. Mobilization of peripheral blood stem cells

with chemotherapy and granulocyte-colony stimulating factor (G-CSF): A randomized

evaluation of different doses of G-CSF. Bone Marrow Transplantation, Vol 29, Suppl

2, S 193, abstr 713 (Poster presentation), 2002.

56. Demirer T, Aylı M, Daglı M, et al. Influence of post-transplant granulocyte-

colony stimulating factor (G-CSF) administration on peritransplant morbidity in patients

undergoing autologous stem cell transplantation. Bone Marrow Transplantation, Vol

29, Suppl 2, S 197, abstr , 2002.

57. Arslan O, Arat M, Soydan E, Coskun HS, Topcuoglu P, Ozcan M, Gurman G,

Demirer T et al. Does donor recipient ABO-incompatibility have any effect on the

course and outcome of allogeneic hematopoietic stem cell transplantation? Bone

Marrow Transplantation, Vol 29, Suppl 2, S 214, abstr 771 (Poster presentation),

2002.

58. Kröger N, Zander AR, Ferrante P, Martinelli G, Janvier M, Moraleda J, Cellerino

G, Zambelli A, Blaise D, Demirer T, Rosti G on behalf of the EBMT Working Party on

Solid Tumors. Low incidence of secondary myelodysplasia (sMDS) and acute leukemia

(sAML) after high-dose chemotherapy as adjuvant therapy for breast cancer patients.

Bone Marrow Transplantation, Vol 29, Suppl 2, S 220, abstr 788 (Poster

presentation), 2002.

59. Demirer T, Aylı M, Daglı M,et al. Mobilization of peripheral blood stem cells with

chemotherapy and granulocyte-colony stimulating factor (G-CSF): A randomized

evaluation of different doses of G-CSF. ASCO Proceedings, Vol: 21, Part 1 0f 2,

Poster discussion, Abstr 1667, page 417a, 2002.

61

61

60. Aylı M, Demirer T, Aylı M, Daglı M, et al. Influence of post-transplant

granulocyte-colony stimulating factor (G-CSF) administration on peritransplant morbidity

in patients undergoing autologous stem cell transplantation. ASCO Proceedings, Vol:

21, Part 1 0f 2, Poster , Abstr 1690, page 423a, 2002.

61. Kröger N, Zander AR, Ferrante P, Martinelli G, Janvier M, Moraleda J, Cellerino

G, Zambelli A, Blaise D, Demirer T, Rosti G on behalf of the EBMT Working Party on

Solid Tumors. Incidence of secondary myelodysplasia (sMDS) and acute leukemia

(sAML) after high-dose chemotherapy as adjuvant therapy for breast cancer patients.

ASCO Proceedings, Vol: 21, Part 2 0f 2, Abstr 2035, page 56b, 2002.

62. Demirer T, Genc Y, Ayli M, et al. Influence of post-transplant granulocyte-colony

stimulating factor (G-CSF) administration on peritransplant morbidity in patients

undergoing autologous stem cell transplantation. The Hematology Journal, Vol: 3,

Suppl 1, abstr: 84 (Poster presentation), pp 37, June 2002.

63. Demirer T, Ayli M, Dagli M, et al. The effect of post-transplant spironolactone

administration on daily potassium requirements in patients undergoing autologous stem

cell transplantation. The Hematology Journal, Vol: 3, Suppl 1, abstr: 83 (Poster

presentation), pp 37, June 2002.

64. Demirer T. CD34+ cells in the field of hematopoietic stem cell transplantation.

IXth International Symposium on Biomedical Science and Technology, BIOMED 2002,

Abstr: I-14, pp:017, (Oral Presentation) .

65. Demirer T. The EBMT Solid Tumors Working Party (STWP) registry: 2001

report. 2nd International Congress on advances in Hematology-Oncology and

62

62

BMT, Tehran, IRAN, September 25-29, pp:14, 2002, (Oral Presentation).

66. Demirer T. High-dose chemotherapy (HDC) in the adjuvant setting in patients

with high risk primary breast cancer. . 2nd International Congress on advances in

Hematology-Oncology and BMT, Tehran, IRAN, September 25-29, pp:25, 2002,

(Oral Presentation).

67. Aylı M, Demirer T, Konuk N, et al. Influence of post-transplant recombinant

human granulocyte colony stimulating factor (RhG-CSF) administration on

peritransplant morbidity in patients undergoing autologous stem cell transplantation.

Annals of Oncology, Vol:13, Supplement 5, pp 30, 2002.

68. Demirer T, Uysal A, Ayli M, et al. High dose thiotepa, melphalan and carboplatin

followed by autologous stem cell transplantation in patients with advanced breast

cancer. A retrospective evaluation. Annals of Oncology, Vol: 13, Supplement 5,

Poster 205, pp 57, 2002.

69. Rosti G, De Giorgio U, Papiani G, Wandt H, Siegert W, Kozak T, Bornhauser M,

Kulekci A, Demirer T. High-dose chemotherapy in extragonadal germ cell tumor: first

results of the EBMT registry. Bone Marrow Transplantation, Vol: 31, Suppl:1, pp:

S35, abstract: 0272, 2003, (Oral Presentation).

70. Bregni M, Peccatori J, Bernardi M, Pedrazzoli P, Siena S, Aglietta M, Slavin S,

Blaise D, Demirer T, Niederwieser D, Bay JO. Allogeneic stem cell transplantation in

ovarian cancer: the EBMT experience. Bone Marrow Transplantation, Vol: 31,

Suppl:1, pp: S36, abstract: 0275, 2003, (Oral Presentation).

71. Kröger N, Damon L, Zander A, Wandt H, Derigs G, Ferrante P, Demirer T, Rosti

63

63

G on behalf of the EBMT Solid Tumors Working Party. Secondary acute leukemia

following mitoxantronebased high-dose chemotherapy for primary breast cancer. Bone

Marrow Transplantation, Vol: 31, Suppl:1, pp: S193, Poster abstract: P687, 2003.

72. Demirer T, Ayli M, İlhan O, Koc H, Dagli M, Arat M, Fen T, Dincer S, Ozet G,

Akan H, Uysal A. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by

autologous stem cell transplantation in patients with advanced breast cancer: a

retrospective evaluation. Bone Marrow Transplantation, Vol: 31, Suppl:1, pp: S195,

Poster abstract: P695, 2003.

73. Demirer T, Ledermann J, Leyvraz S, Niederwieser D, Blaise D, Aglietta M,

Ueno N, Rosti G. The Status of bone marrow transplant clinical trials (Teaching

lecture). European Journal of Cancer. Vol: 1, No:5, pp 14, 2003.

74. Bregni M, Barkholt L, Peccatori J, Pedrazzoli P, Remberger M, Carminati O,

Ciceri F, Siena S, Martino R, Sierra J, Brune M, Bekassy AN, Corradini P, Rosti G,

Demirer T, Ringden O, Niederwieser D. Graft versus tumor effect following reduced-

intensity allogeneic stem cell transplantation in renal cell cancer . On behalf of the

EBMT Solid Tumors Working party. BLOOD, Vol: 102, No:11, part 1, pp 198a, abstract

692, 2003 (Oral presentation).

75. Barkholt L, Bregni M, Peccatori J, Pedrazzoli P, Remberger M, Carminati O,

Ciceri F, Siena J, Martino R, Sierra J, Bruness M, Lenhoff S, Corradini P, Rosti G,

Demirer T, Niederwieser D, Ringden O, on behalf od EBMT Solid Tumors Working

Party. Graft versus tumor effect following reduced intensity allogeneic stem cell

transplantation in renal cell cancer. Bone Marrow Transplantation, Vol:33, Suppl 1,

64

64

abstract 97, S4, 2004, (Oral Presentation).

76. Rosti G, Papiani G, Wandt H, Leyvraz S, Demirer T, Giorgi U De on behalf of

EBMT Solid Tumors Working Party. Early high dose chemotherapy for adult patients

with extragonadal non-seminomatouse germ cell tumors of the mediastinum and

retroperitoneum. Bone Marrow Transplantation, Vol:33, Suppl 1, abstract 265, S39,

2004, (Oral Presentation).

77. Giorgi U De, Rosti G, Slavin S, Yaniv I, Harousseau JL, Tobler A, Ladenstein R,

Demirer T, Dini G on behalf of the Solid Tumors and Paediatric Diseases Working

Parties. Long-term follow up after high-dose chemotherapy for paediatric patients with

extragonadal germ cell tumors. Bone Marrow Transplantation, Vol:33, Suppl 1,

abstract 268, S40, 2004, (Oral Presentation).

78. Demirer T, Soydan E, Fen T et al. High-dose thiotepa, melphalan, and

carboplatin followed by autologous peripheral blood stem cell transplantation in patients

with lymphoma- a retrospective evaluation. . Bone Marrow Transplantation, Vol:33,

Suppl 1, abstract P904, S250, 2004.

79. Bregni M, Peccatori J, Barkholt L, Ringden O, Pedrazzoli P, Martino R, Lenhoff

S, Corradini P, Demirer T, Niederwieser D. Prognostic factors for survival in renal cell

cancer patients undergoing allogeneic stem cell transplantation: A report from the EBMt

Solid Tumors Working Party. ASCO Proceedings, Vol: 22, No: 14S,, Abstr 6666, page

599s, 2004.

80. Giorgi U. De, Demirer T, Wandt H, et al. Second line high-dose chemotherapy

in patients with extragonadal nonseminomatous germ cell tumors: the experience of the

European Group for Blood and Marrow Transplantation (EBMT). Annals of Oncology,

Vol: 15, Suppl:3, iii 121, abstract (Poster) 452P, 2004.

65

65

81. Bay JO, Durando X, Linassier C, Biron P, Kwiatkowski F, Verelle P, Rosti G,

Demirer T, on behalf of the Solid Tumors Working party. High dose BCNU followed by

autologous hematopoietic stem cell transplantation in supratentorial high-grade

malignant gliomas: An EBMT retrospective analysis of 218 patients. Bone Marrow

Transplantation, Vol: 35, Suppl 2, Abstract (Oral Presentation) 0272, S53, 2005,

82. Grosso F, Corradini P, Carrabba M, Castagna L, Pedrazzoli P, Gobel U, Demirer

T, Niederwieser D, on behalf of Solid Tumors Working party. Allogeneic stem cell

transplantation in advanced soft tissue sarcomas: a retrospective analysis on the EBMT

STWP. Bone Marrow Transplantation, Vol: 35, Suppl 2, Abstract (Oral Presentation)

0272, S53, 2005,

84. İlhan O, Topcuoglu P, Arat M, Soydan E, Özcan M, Gürman G, Demirer T, Akan

H et al. Allogeneic hematopoietic stem cell transplantation in acute myeloblastic

leukemia.: İbn-i Sina experience (1989-2004). Bone Marrow Transplantation, Vol: 35,

Suppl 2, Abst (Oral Presentation) 0272, S53, 2005,

85. Pervin Topçuoğlu, Taner Demirer et all. When to start G-CSF after mobilization

regimen? Any impact on stem cell collection efficiency (abstract 141, sayfa: 231). The

15th Congress of the ESFH (Transfusion and Apheresis Science, 2005; 33(2)

86. M Özcan, M K Yüksel, P Topçuoğlu, E A Soydan, S K Toprak, M Beksaç, A Uysal,

H Akan, T Demirer, et all. Addition of ANTI-CD20 to high dose chemotherapy with

autologous peripheral blood stem cell transplantation prolong disease free survivalin

non-Hodgkin’s lymphomas: A Matched-controlled analysis (Abstract: 573 Poster: 480).

XXX. World Congress of the International Society of Hematology. Turkish Journal of

Haematology, 2005 22(3) (supplement)

66

66

87. P Topçuoğlu, F EKiz, E A Soydan, M K Yüksel, S K Toprak, M Özcan, Ö Arslan, G

Gürman, T Demirer, et all. How to calculate the quantity of CD34(+) cells infused? A

single center cohort study based on actual, ideal or adjusted ideal body body weight

(Abstract: 668 Poster: 575). XXX. World Congress of the International Society of

Hematology. Turkish Journal of Haematology, 2005 22(3) (supplement)

88. O İlhan, P Topçuoğlu, M Arat, E A Soydan, M K Yüksel, S K Toprak, Ö Arslan, M

Özcan, G Gürman, T Demirer et all. Allogeneic hematopoietic cell transplantation in

acute myeloblastic leukemia: Ankara University Experience (Abstract: 672 Poster: 579).

XXX. World Congress of the International Society of Hematology. Turkish Journal of

Haematology, 2005 22(3) (supplement)

89. P Topçuoğlu, Ö T İyidir, K Dalva, E A Soydan, M K Yüksel, S K Toprak, H Koç, A

Uysal, M. Beksaç, M Özcan, M Arat, T Demirer et all. When to start G-CSF after

mobilization regimen? Any impact on stem cell collection efficiency (Abstract: 759

Poster: 666). XXX. World Congress of the International Society of Hematology. Turkish

Journal of Haematology, 2005 22(3) (supplement)

90. Gökhan Kabaçam, Mutlu Arat, Ender Soydan, Klara Dalva, Erol Ayyıldız, Günhan

Gürman, Taner Demirer, Hamdi Akan, Meral Beksaç, Osman İlhan. Factors effecting

peripheral stem cell collection in multiple myeloma patients.(poster 612), S:127.

Haematologica 2005, suppl 10th International Myeloma Workshop, Sydney, April 10-14,

2005

91. O. Ilhan, P. Topcuoglu, M. Arat, E. Soydan, S.K. Toprak, M.K. Yuksel, C. Ustün, H.

Celebi, I. Dilek, O. Arslan, M. Ozcan, G. Gurman, T. Demirer, H. Akan, M. Beksac, A.

Uysal, N. Konuk, H. Koc. Allogeneic haematopoietic cell transplantation in acute

67

67

myeloblastic laeukemia: Ibni Sina experience (1989 - 2004) 31st Annual Meeting of the

European Group for Blood and Marrow Transplantation 20-23 March 2005

92. P. Topçuoğlu, ÖT. İyidir, K. Dalva, EA. Soydan, MK. Yüksel, SK. Toprak, H Koç,

VA Uysal, M. Beksaç, M. Özcan, Ö. Arslan, N. Konuk, M. Arat, T. Demirer, O. İlhan.

When to start G-CSF after mobilization regimen? Any impact on stem cell collection

efficiency. Turk J Haematol 2005; 22: 312 (P 666)

93. Aglietta M, Barkholt L, Niederwieser D, Ringden O, Demirer T. Allogeneic

hematopoietic cell transplantation after reduced intense conditioning as adoptive cell

therapy in resistant metastatic colorectal carcinoma. The European Experience.

Journal of Clinical Oncology, Vol: 24, No: 18s, Part I, 2006.

94. Arat M, Cengiz G, Ayyıldız E, Topçuoğlu P, Arslan Ö, Özcan M, Gürman G,

Dalva K, Beksaç M, Demirer T, et all . Retrospective validation of an apheresis cycle

calculator of autologous PBSC collection in myeloma and malignant lymphoma

patients. Abstract Book, ESFH 2006 Meeting, 20-21 June 2006, Umea, Sweden (Oral

Presentation).

95. Arat M, Soydan E, Cengiz G, Ayyildiz E, Topcuoglu P, Arslan O, Ozcan M,

Gurman G, Dalva K, Beksac M, Demirer T, et all. Retrospective validation of an

apheresis cycle calculator on autologous PBSC collection in myeloma and malignant

lymphoma patients. CYTOTHERAPY 8: Suppl. 1, 2006.

96. Aglietta M, Barkholt L, Caravelli D, Omazig B, Ciccone G, Niederwieser D, Ringden

O, Demirer T on behalf of EBMT STWP. Allogeneic hematopoietic cell transplantation

after reduced intense conditioning as adoptive cell therapy in resistant metastatic

colorectal carcinoma. The European Experience. 24, No 18S Part I of II, Poster 3596, J

Clin Oncol, 2007.

68

68

97. Arat M, Gurman G, Demirer T, Beksaç M et al. Time intervals preceeding

autologous stem cell transplantation in multiple myeloma patients : a single center

intent to transplant analysis. Bone Marrow Transplantation, Vol: 39, Suppl 1, Abstract

R1172, S322, 2007.

98. Serbest E, Ozcan M, Arslan O, Demirer T, Beksac M, Arat M et al. The impact of

disparity in short tandem repeats analysis on the outcome of allogeneic haematopoietic

cell transplantation from HLA identical sibling donors. Bone Marrow Transplantation,

Vol: 39, Suppl 1, Abstract P799 , S197-198, 2007.

99. Soydan E, Arslan O, Ozcan M, Demirer T, Arat M et al. The impact of

histopathological subtype of cutaneous chronic GVHD on alloHSCT outcome: lichenoid

versus sclerodermoid. Bone Marrow Transplantation, Vol: 39, Suppl 1, Abstract P549,

S106-107, 2007.

100. Ugur Bİlgin A, Soydan E, Akan H, Gurman G, Demirer T, Arat M et al. The

impact of pretransplant imatinib use in allogeneic HSCT for CML: a single center

comparative analysis. Bone Marrow Transplantation, Vol: 39, Suppl 1, Abstract P444,

S68-69, 2007,

101. P. Topcuoglu, S. Civriz Bozdağ, B. Ceydilek, MK Yüksel, ŞM Bakanay, Ö.

Arslan, T Demirer, et all. EMA as a salvage regimen in patiens with refractory/relapse

AML: A single center experience. Turk J Hematol 2007; 1 (suppl 1): 110-111

102. E. Serbest, P. Topcuoglu, K. Dalva, E.A. Soydan, O. Arslan, M. Ozcan, T.

Demirer, et all. The impact of disparity in short tandem repeats analysis on the

69

69

outcome of allogeneic haematopoietic cell transplantation from HLA-identical sibling

donors. Haematologica, the Hematology Journal 2007; 92 (suppl 1): 517

103. Bay J.O, Tabrizi R, Blaise D, Viens P, Ehninger G, Slavin S, Rosti G, Demirer T ,

Bregni M. Allogeneic stem cell transplantation in ovarian cancer. The EBMT

experience. Bone Marrow Transplantation, S 310, p 998, 2008.

104. Bertuzz. A, Tienghi A, Pedrazzoli P, Castagna L, Demirer T, Bregni M. Long

term outcome in adult Ewing’s sarcoma patients treated with high-dose chemotherapy :

results of a retrospective analysis of the EBMT. Bone Marrow Transplantation, S 311, p

999, 2008.

105. Demirer T, Ueno N, Bregni M, Berry D, on behalf of the MDACC-EBMT Meta-

analysis Group. High-dose chemotherapy with a stem cell support-versus-standard

dose chemotherapy: meta-analysis of individual patient data from 15 randomised breast

cancer trial. (Oral Presentation). Bone Marrow Transplantation, S 311, p 999, 2008.

106. DA Berry, NT Ueno, MM Johnson, X Lei, D Smith, J Caputo, L Yancey, M

Bregni, T Demirer, on behalf of MDACC-EBMT Meta-analysis Group. High-dose

chemotherapy with autologous stem-cell support versus standard-dose chemotherapy:

meta-analysis of individual patient data from 6 randomized metastatic breast cancer

trials. 31st Annual San Antonio Breast Cancer Symposium. Abstr No: 551494, 2008.

107. Demirer T, Ueno N, Johnson M, Bregni M, Berry DA, on behalf of the EBMT-

MDACC Meta-analysis group. High-dose chemotherapy with autologous stem-cell

support versus standard-dose chemotherapy: meta-analysis of individual patient data

from 6 randomised metastatic breast cancer trials. Oral Presentation. Bone Marrow

70

70

Transplantation, Vol: 43, Suppl 1, O156, S16, 2009.

108. Civriz BS, Topcuoglu P, Bakanay s, Arat M, Beksac M, Arslan Ö, Demirer T,

Gurman G, Ozcan M. The effect of rituximab in first line therapy results of autologous

hematopoietic stem cell transplantation in relapsed non-Hodgkin’s lymphoma patients.

Bone Marrow Transplantation, Vol: 43, Suppl 1, O156, S16, 2009.

109. Demirer T, Ueno N, Johnson M, Bregni M, Berry DA, on behalf of the EBMT-

MDACC Meta-analysis group. High-dose chemotherapy with autologous stem-cell

support versus standard-dose chemotherapy: meta-analysis of individual patient data

from 6 randomised metastatic breast cancer trials. Oral Presentation. Bone Marrow

Transplantation, Vol: 43, Suppl 1, O156, S16, 2009.

110. Civriz BS, Topcuoglu P, Bakanay S, Arat M, Beksac M, Arslan Ö, Demirer T,

Gurman G, Ozcan M. The effect of rituximab in first line therapy results of autologous

hematopoietic stem cell transplantation in relapsed non-Hodgkin’s lymphoma patients.

Bone Marrow Transplantation, Vol: 43, Suppl 1, O156, S16, 2009.

111. S.C Bozdağ, P Topcuoglu, M. Arat, T. Demirer, M. Beksac, N. Konuk, A. Uysal,

G. Gürman. Comparison of two different chemotherapy regimens for peripheral blood

stem cell mobilization in Lymphoma. Bone Marrow Transplantation. Vol 45, Suppl 2,

P841, 2010.

2013-2014 (Yayın Yılı)

112.Comparison Of Flow Cytometric and Clinical Findings In Patients

71

71

With Paroxysmal Nocturnal Hemoglobinuria

By: Demirer, Taner; Baslar, Suphi; Uysal, Vasif Akin; et al.

Conference: 55th Annual Meeting of the American-Society-of-Hematology

Location: New Orleans, LA Date: DEC 07-10, 2013

Sponsor(s): Amer Soc Hematol

BLOOD Volume: 122 Issue: 21 Meeting Abstract: 4877 Published: NOV 15

2013

113. Aldehyde hydrogenase activity in mobilized peripheral stem cell

products and its relationship with engraftment

By: Bozdag, S. Civriz; Topcuoglu, P.; Ozkan, M.; et al.

Conference: 39th Annual Meeting of the European-Group-for-Blood-and-Marrow-

Transplantation (EBMT) Location: London, ENGLAND Date: APR 07-10, 2013,

European Grp Blood & Marrow Transplantat (EBMT)

BONE MARROW TRANSPLANTATION Volume: 48 Supplement: 2 Pages:

S196-S196 Published: APR 2013

114. Atilla E, Ataca P, Bozdag SC, Toprak SK, Yuksel MK, Topcuoglu P, Arslan O,

Ozcan M, Demirer T, Ilhan O, Akan H, Beksac M, Gurman G,’Is initial CD3+ T cell dose

in donor lymphocyte infusion for relapsed hematological malignancies a prognostic

determinant?’, ASH Meeting, Chicago, USA, BLOOD, 2013.

72

72

115. Management of Hemorrhagic Cystitis after Allogeneic

Hematopoietic Stem Cell Transplantation

By: Gurman, Gunhan; Atilla, Erden; Ozen, Mehmet; et al.

Conference: BMT Tandem Meetings Location: Grapevine, TX Date: FEB 26-MAR

02, 2014 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION Volume:

20 Issue: 2 Supplement: 1 Pages: S194-S195 Meeting Abstract: 290

Published: FEB 2014

116. Gunduz M, Ataca P, Ozen M, Atilla E, Bozdag SC, Toprak SK, Topcuoglu P,

Ozcan M,DemirerT, Beksac M, Akan H, Gurman G, Arslan O, ‘Do FMS-like Tyrosine

Kinase 3 and Nucleophospmin 1 Gene Mutation Really Effect Survival in Acute Myeloid

Leukemia?’,Orlando, FL, USA. Poster presentation,57th ASH Meeting, BLOOD, 2014.

117. Atilla E, Sahin U, Ataca P, Bozdag SC, Toprak SK, , Arslan O, Demirer T, Akan

H, Gurman G, Beksac M, Ilhan O, Konuk N, Ozcan M, ‘Is R-CODOX-M/IVAC Inferior to

Other Regimens in Burkitt’s Lymhoma: A Single Center Experience’, Orlando, FL, USA.

57th ASH Meeting Poster presentation, BLOOD, 2014.

2015 (Yayın Yılı)

118. Ataca P, Atilla E, Arslan O, Ozcan M, Demirer T, Akan H, Beksac M, Konuk N,

Gurman G, Ilhan O, ‘Are there any optimal cell doses for graft repopulation in the Bone

Marrow-Derived Allogeneic Hematopoietic Stem Cell Transplantations?’, Istanbul,

Turkey, 41th EBMT Meeting, Poster presentation, Bone Marrow Transplantation,

2015.

73

73

119. Atilla E, Ataca P, Ozcan M, Demirer T, Ilhan O, Akan H, Beksac M, Konuk N,

Gurman G, ‘Upper and Lower Respiratory Tract Infections by Respiratory Viruses by

Respiratory Viruses in Adult Recipients of Allogeneic Hematopoietic Stem Cell

Transplantation: Single Center Experience’. 41st EBMT Meeting, Istanbul, Turkey,

Poster Presentation, Bone Marrow Transplantation, 2015.

120. Topcuoglu P, Yuksel MK, Arslan O, Ozcan M, Demirer T, Ilhan O, Akan H,

Konuk N, Gurman G,’ The Relapse in acute leukemia after allogeneic hematopoietic

stem cell transplantation: No approaches have been superior yet’. . 41st EBMT Meeting,

Istanbul, Turkey, Poster Presentation, Bone Marrow Transplantation, 2015.

121. Atilla E, Gunduz M, Ataca P, Bozdag SC, Toprak SK, Yuksel MK, Topcuoglu P,

Arslan O, Ozcan M, Demirer T, Ilhan O, Akan H, Beksac M, Konuk N, Gurman

G,’Autologous Stem Cell Transplantation in Elderly Patients with Myeloma or

Lymphoma’, Best of ASBMT Tandem Meetings, Poster Presentation May 2015

Ankara, Turkey, Best Abstract Award.

122. Atilla E, Ataca P, Bozdag SC, Toprak SK, Yuksel MK, Topcuoglu P, Arslan O,

Ozcan M, Demirer T, Ilhan O, Akan H, Beksac M, Gurman G,’Is initial CD3+ T cell

dose in donor lymphocyte infusion for relapsed hematological malignancies a

prognostic determinant?’, ASH Meeting on Hematologic Malignancies, Poster

Presentation September 2015 Chicago USA

123. Atilla E, Gunduz M, Ataca P, Bozdag SC, Toprak SK, Yuksel MK, Topcuoglu P,

Arslan O, Ozcan M, Demirer T, Ilhan O, Akan H, Beksac M, Konuk N, Gurman

G,’Autologous Stem Cell Transplantation in Elderly Patients with Myeloma or

Lymphoma’, 20th EHA Meeting, Poster Presentation June 2015 Vienna, Austria

74

74

124. Ataca P, Atilla E, Aydin T, Merter M, Bozdag SC, Toprak SK, Yuksel MK,

Topcuoglu P, Arslan O, Ozcan M, Demirer T, Ilhan O, Beksac M, Akan H, Konuk N,

Gurman G, ‘Allogeneic Stem-Cell Transplantation for Hodgkin and non-Hodgkin

Lymphoma’ 5th ICLLM Meeting, Poster Presentation May 2015 Istanbul, Turkey..

125. Gunduz M, Atilla E, Ataca P, Pekcan G, Bozdag SC, Toprak SK, Yüksel MK,

Topcuoglu P, Arslan O, Ozcan M, Demirer T, Ilhan O, Akan H, Beksac M, Konuk N,

Gurman G. Autologous Stem Cell Transplantation in Elderly Patients ( >=60 years) with

Myeloma or Lymphoma: Single Center Experience 41th EBMT Meeting, Poster

Presentation March 2015 Istanbul, Turkey

126. Ataca P, Atilla E, Altas U, Bay M, Dalva K, Bozdag SC, Toprak SK, Yüksel MK,

Topcuoglu P, Arslan O, Ozcan M, Demirer T, Akan H, Beksac M, Konuk N, Gurman G,

Ilhan O. Are there any optimal cell doses for graft repopulation in the Bone Marrow-

Derived Allogeneic Hematopoietic Stem Cell Transplantations?41th EBMT Meeting,

Poster Presentation March 2015 Istanbul, Turkey.

127. Pekcan G, Ateşoglu B, Merter M, Topcuoglu P, Bozdag SC, Toprak SK, Yüksel

MK, Ates O, Özcan M, Demirer T. Different Doses of Anti-Thymocyte Globulin (ATG) in

the Conditioning Regimen for Allogeneic Hematopoetic Stem Cell Transplantation 41th

EBMT Meeting, Poster Presentation March 2015 Istanbul, Turkey.

128. Yuksel MK, Pekcan G, Edipoğlu E, Bay M, Civriz S, Toprak SK, Topcuoglu P,

Arslan O, Ozcan M, Beksac M, Demirer T, Akan H, Konuk N, Gurman G, Ilhan O. Is it

possible to overcome the catastrophic complications of Hematopoietic Stem Cell

Transplantation (HSCT) using Plasma Exchange (PE)?: A Single Center's Experience

41th EBMT Meeting, Poster Presentation March 2015 Istanbul, Turkey.

75

75

129. Bozdag SC, Kırcalı E, Ataca P, Atilla E, Bay M, Toprak SK, Yüksel MK, Topcuoglu

P, Arslan O, Özcan M, Demirer T, İlhan O, Akan H, Beksac M, Konuk N, Gurman G. Is

there an optimum CD3+T cell dose for donor lymphocyte infusion? 41th EBMT Meeting,

Poster Presentation March 2015 Istanbul, Turkey.

130. Sahin U, Erdal H, Bozdag SC, Toprak SK, Yuksel MK, Topcuoglu P, Arslan O,

Ozcan M, Demirer T, Ilhan O. Impact of Pre-transplant Serum Ferritin on Outcomes of

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia. 41th EBMT

Meeting, Poster Presentation March 2015 Istanbul, Turkey

131. Topcuoglu P, Gultay D, Ozturk N, Kılıc O, Okay M, Karadag YE, Cınar H, Ataca P,

Atilla E, Bozdag SC, Toprak SK, Yüksel MK, Arslan O, Özcan M, Demirer T, Akan H,

Beksac M, Konuk N, Gurman G. Generic (Bioequivalent) Melphalan Has Similar

Efficacy and Toxicity but Lower Cost in the Conditioning Regimen for Autologous

Hematopoietic Stem Cell Transplantation 41th EBMT Meeting, Poster Presentation

March 2015 Istanbul, Turkey.

132. Gurman G, Ataca P, Aydın T, Atilla E, Bozdag SC, Toprak SK, Yüksel MK,

Topcuoglu P, Ozcan M, Demirer T. Allogeneic stem cell transplantation results in our

myelodysplastic syndrome (MDS) patients. Annual Meeting of the American-Society-

of-Clinical-Oncology (ASCO), Haziran 2015 Chicago, USA.

133. Gurman G, Ataca P, Atilla E, Bozdag SC, Toprak SK, Yuksel MK, Demirer T, Akan H,

Arslan O, Topcuoglu P, Beksac M, Ilhan O, Ozcan M. Positive Impact of Chronic Graft-Versus

Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients.

December 3, 2015; Blood: 126 (23)

76

76

134. Mustafa Merter, Erden Atilla, Ugur Sahin, Sinem Civriz Bozdag, Meltem Kurt

Yuksel, Pervin Topcuoglu, Onder Arslan, Muhit Ozcan, Taner Demirer, Gunhan

Gurman, Osman Ilhan, Hamdi Akan, Meral Beksac, Selami Kocak Toprak. Comparison

of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in

Allogeneic Hematopoietic Stem Cell Transplantation Blood 2015 126:5456; published

ahead of print December 4, 2015

135. Erden Atilla, Pinar Ataca, Selami Kocak Toprak, Meltem Kurt Yuksel, Pervin

Topcuoglu, Onder Arslan, Muhit Ozcan, Taner Demirer, Osman Ilhan, Meral Beksac,

Hamdi Akan, Gunhan Gurman, Sinem Civriz Bozdag.Is Initial CD3+ T Cell Dose in

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic

Determinant? Blood 2015 126:5483; published ahead of print December 4, 2015

2016 (Yayın Yılı)

136. THERAPEUTIC PLASMA EXCHANGE FOR THROMBOTIC

MICROANGIOPATHY.By: E. Atilla, P. Ataca, U. Sahin, S.C. Bozdag, S.K. Toprak, M.K.

Yuksel,P. Topcuoglu, O. Arslan, T. Demirer, M. Ozcan, H. Akan, M. Beksac,G. Gurman,

O. Ilhan.Conference: 24th Biennial International Congress on Thrombosis / EMLTD

Congress Location: Istanbul, TURKEY Date: MAY 04-07, 2016

137. THERAPEUTIC THROMBOCYTAPHERESIS: HIGHER PLATELET COUNTS

SHOULD MATTER. By: Narli, Z.; Sahin, U.; Bozdag, S. C.; M.K. Yuksel, S.K. Toprak,

P. Topcuoglu,M. Ozcan, O. Arslan, T. Demirer, M. Beksac, G. Gurman, O. Ilhan: 24th

77

77

Biennial International Congress on Thrombosis / EMLTD Congress Location: Istanbul,

TURKEY Date: MAY 04-07, 2016 Sponsor(s): EMLTD. THROMBOSIS

RESEARCH Volume: 141 Supplement: 1 Pages:S81-S82 Meeting

Abstract: C0323 Published: MAY 2016 (Poster)

138. Effect of Cytomegalovirus Reactivation on Prognosis After Allogeneic

Transplantation for Acute Leukemia with Active Disease Conditioned with a Sequential

Regimen and Anti-Thymocyte Globulin. By: M. Gunduz, M. Kurt Yuksel,*, U. Sahin, M.

Merter, Z. Narli,Ozdemir, S. Civriz Bozdag, S. K. Toprak, P. Topcuoglu,O. Arslan, M.

Ozcan, T. Demirer, O. Ilhan, H. Akan,M. Beksac, G. Gurman. Conference: 42nd

Annual Meeting of the European-Society-for-Blood-and-Marrow-

Transplantation Location: Valencia, SPAIN Date: APR 03-06, 2016

139. Efficacy of High Dose Corticosteroid Premedication for the Prevention of Anti-

thymocyte Globulin Related Side Effects. By: M. Merter, U. Sahin, E. Atilla, S. Civriz

Bozdag, M. Kurt Yüksel,P. Topcuoglu, O. Arslan, M. Ozcan, T. Demirer, O. Ilhan, H.

Akan, M. Beksac, G. Gurman, S. K. Toprak,*Conference: 42nd Annual Meeting of the

European-Society-for-Blood-and-Marrow-Transplantation Location: Valencia,

SPAIN Date: APR 03-06, 2016

140. Therapeutic Plasma Exchange for Thrombotic Microangiopathy

Osman Ilhan, Erden Atilla, Pinar Ataca Atilla, Sinem Civriz Bozdag, Selami

Toprak, Pervin Topcuoglu,Hamdi Akan, Taner Demirer, Meral Beksac, Onder Arslan,

Muhit Ozcan and Gunhan Gurman. ASH Annual Meeting 2016 3-6 December 2016.

Blood 2016 128:4939

141. Comparison of Reduced Intensity Conditioning (RIC) Regimen and Myeloablative

Conditioning (MAC) Regimen in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-

78

78

HSCT) for Adult Patients with Acute Leukemia. Gunhan Gurman, Gozde Aydemir

, Erden Atilla, Pinar Atilla, Onder Arslan, Muhit Ozcan, Taner Demirer, Osman Ilhan, H

amdi Akan and Meral Beksac. ASH Annual Meeting 2016 3-6 December 2016.

Blood 2016 128:5757

142. Ilhan O, Atilla E, Ataca P, Bozdag SC, Toprak SK, Yüksel MK, Topcuoglu P,

Arslan O, Ozcan M, Demirer T, Akan H, Beksac M, Gurman G. Age as a dicision factor

for doing autuologous stem cell transplantation in fit patients with myeloma and

lymphoma. ASCO Annual Meeting. J Clin Oncol 34, 2016 (suppl; abstr e 19001)